epitope_epitope id,epitope_description,epitope_starting position,epitope_ending position,epitope_antigen name,epitope_parent protein,related object_epitope relationship,related object_description,related object_parent protein,mhc_allele name,mhc_allele evidence code,assay_method/technique,agg_label,total_count,percentage_pos,len
1852488,AEVDQDGVVM,,,,,neo-epitope,AEVDEDGVVM,Neurogenic locus notch homolog protein 4,HLA-B*44:03,Cited reference,ELISA,0,2,0.0,10
1852507,AILLGAEEK,,,,,neo-epitope,AKLLGAEEK,Epidermal growth factor receptor,HLA-A*11:01,Cited reference,ELISA,0,2,0.0,9
1852513,AITSPKANK,,,,,neo-epitope,AIKELREATSPKANK,Epidermal growth factor receptor,HLA-A*11:02,Cited reference,ELISA,0,2,0.0,9
1852603,AQPAVQSAF,,,,,neo-epitope,AQAAVQSAF,Cyclin-dependent kinase 13,HLA-A*02:06,Cited reference,ELISA,0,2,0.0,9
1852610,ARLPVGAYEV,,,,,neo-epitope,ALLPVGAYEV,Aquaporin-12B,HLA-A*02:01,Cited reference,ELISA,0,2,0.0,10
1852613,ARRASKARL,,,,,neo-epitope,ARRASKALL,Aquaporin-12B,HLA-C*07:02,Cited reference,ELISA,0,2,0.0,9
1852679,CMSCTVNLL,,,,,neo-epitope,RMSCTVNLL,Dedicator of cytokinesis protein 2,HLA-A*02:07,Cited reference,ELISA,0,2,0.0,9
1852699,CVVTEVFLL,,,,,neo-epitope,CGVTEVFLL,Olfactory receptor 5L2,HLA-A*02:06,Cited reference,ELISA,0,2,0.0,9
1852773,DVSDNEPDLYR,,,,,neo-epitope,DVSDNEPDHYR,"Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN",HLA-A*33:01,Cited reference,ELISA,0,2,0.0,11
1863981,EAAPPSTSM,,,,,neo-epitope,macrophage colony-stimulating factor 1 receptor precursor,,HLA-C*03:04,MHC binding prediction,ELISA,0,2,0.0,9
1852786,EASGITYEY,,,,,neo-epitope,EASGITYED,Interleukin-6 receptor subunit beta,HLA-A*01:01,Cited reference,ELISA,0,2,0.0,9
1852801,EECLWMAVL,,,,,neo-epitope,EECLGMAVL,Tyrosine-protein kinase JAK2,HLA-B*40:02,Cited reference,ELISA,0,2,0.0,9
1852854,EPLSYSLLQR,,,,,neo-epitope,EPLSYSRLQR,ALK tyrosine kinase receptor,HLA-A*33:01,Cited reference,ELISA,0,2,0.0,10
1852887,EVVRHCPHHER,,,,,neo-epitope,EVVRRCPHHER,Cellular tumor antigen p53,HLA-A*33:03,Cited reference,ELISA,0,2,0.0,11
858879,EVYEGVWKK,255.0,263.0,Proto-oncogene tyrosine-protein kinase ABL1,Tyrosine-protein kinase ABL1,,,,HLA-A*03:01,MHC binding assay,ELISPOT,0,2,0.0,9
1852898,FAKNPHLHY,,,,,neo-epitope,FAKNPHLRY,NT-3 growth factor receptor,HLA-B*15:27,Cited reference,ELISA,0,2,0.0,9
1852899,FAKNPHLHYI,,,,,neo-epitope,FAKNPHLRYI,NT-3 growth factor receptor,HLA-A*02:06,Cited reference,ELISA,0,2,0.0,10
1852911,FEIRARTAA,,,,,neo-epitope,FQIRARTAA,Ephrin type-A receptor 5,HLA-B*40:02,Cited reference,ELISA,0,2,0.0,9
1312425,FGRAKLLGA,,,,,neo-epitope,FGLAKLLGA,Epidermal growth factor receptor,HLA-B*54:01,Cited reference,ELISA,0,2,0.0,9
1852915,FHLKGHEDL,,,,,neo-epitope,FLLKGHEDL,Serine/threonine-protein kinase mTOR,HLA-B*39:01,Cited reference,ELISA,0,2,0.0,9
1392798,FILMGLPHV,,,,,neo-epitope,FILMGLPHA,Olfactory receptor 10G8,HLA-A*02:03,MHC binding prediction,ELISA,0,3,0.0,9
1397705,FPVVNSHSL,,,,,neo-epitope,FAVVNSHSL,Solute carrier family 22 member 15,HLA-C*03:04,MHC binding prediction,ELISPOT,0,2,0.0,9
1852966,FQQEIQILK,,,,,neo-epitope,FQREIQILK,Tyrosine-protein kinase JAK3,HLA-A*11:02,Cited reference,ELISA,0,2,0.0,9
1852968,FRHSLVVPY,,,,,neo-epitope,FRHSVVVPY,Cellular tumor antigen p53,HLA-C*07:02,Cited reference,ELISA,0,2,0.0,9
1852972,FTAAALAGH,,,,,neo-epitope,FSAAALAGH,Endothelial transcription factor GATA-2,HLA-A*11:02,Cited reference,ELISA,0,2,0.0,9
1713770,FTGQFVSEEV,,,,,neo-epitope,FTGQFVTEEV,Saccharopine dehydrogenase-like oxidoreductase,HLA-A*02:06,Cited reference,ELISPOT,0,2,0.0,10
1074750,FYGKTIPWF,161.0,169.0,damage-control phosphatase ARMT1 isoform b [Homo sapiens],Damage-control phosphatase ARMT1,,,,HLA-A*24:02,Statistically inferred by motif or alleles present,ELISA,0,2,0.0,9
1087525,GAQSWLWFA,2482.0,2490.0,Teneurin-3,Teneurin-3,,,,HLA-A*02:11,MHC binding prediction,ELISPOT,0,2,0.0,9
1853001,GDFGLATEK,,,,,neo-epitope,GDFGLATVK,RAF proto-oncogene serine/threonine-protein kinase,HLA-A*11:01,Cited reference,ELISA,0,2,0.0,9
1853009,GEQDHTFRV,,,,,neo-epitope,GERDHTFRV,Histone-lysine N-methyltransferase 2C,HLA-B*44:03,Cited reference,ELISA,0,2,0.0,9
1853012,GEYFTHQIR,,,,,neo-epitope,GEYFTLQIR,Cellular tumor antigen p53,HLA-B*40:01,Cited reference,ELISA,0,2,0.0,9
1853029,GITYEYRPSK,,,,,neo-epitope,GITYEDRPSK,Interleukin-6 receptor subunit beta,HLA-A*30:01,Cited reference,ELISA,0,2,0.0,10
1392856,GLAPGLPSV,,,,,neo-epitope,GLAPGLPSG,XK-related protein 4,HLA-A*02:01,MHC binding prediction,ELISPOT,0,2,0.0,9
1397714,GLNVPVQSNK,,,,,neo-epitope,GRNVPVQSNK,Probable E3 ubiquitin-protein ligase HERC6,HLA-A*03:01,MHC binding prediction,ELISPOT,0,2,0.0,10
1853113,GRMRSLEAL,,,,,neo-epitope,GRMRCLEAL,Serine/threonine-protein kinase mTOR,HLA-B*39:01,Cited reference,ELISA,0,2,0.0,9
1853120,GSLHSGTAK,,,,,neo-epitope,GFLHSGTAK,Cellular tumor antigen p53,HLA-A*11:01,Cited reference,ELISA,0,2,0.0,9
1853125,GSVSFGTVY,,,,,neo-epitope,GSGSFGTVY,RAF proto-oncogene serine/threonine-protein kinase,HLA-C*14:03,Cited reference,ELISA,0,2,0.0,9
542571,GTDPQLLLY,1612.0,1620.0,Chondroitin sulfate proteoglycan 4,Chondroitin sulfate proteoglycan 4,,,,HLA-A*01:01,MHC binding prediction,ELISPOT,0,3,0.0,9
1853141,HCFNDVTAI,,,,,neo-epitope,QCFNDVTAI,Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas,HLA-A*32:01,Cited reference,ELISA,0,2,0.0,9
1861527,HLARHRHLM,,,,,neo-epitope,HPARHRHLM,Testis-expressed protein 2,HLA-A*66:01,MHC binding prediction,ELISPOT,0,2,0.0,9
1853186,HPLCGYHEQV,,,,,neo-epitope,Epidermal growth factor receptor precursor,,HLA-B*07:02,Cited reference,ELISA,0,2,0.0,10
1853192,HRGCSIWPR,,,,,neo-epitope,Proto-oncogene tyrosine-protein kinase receptor Ret,,HLA-A*33:01,Cited reference,ELISA,0,2,0.0,9
1853193,HSHFWDNSK,,,,,neo-epitope,RSHFWDNSK,Exostosin-1,HLA-A*31:01,Cited reference,ELISA,0,2,0.0,9
1853209,IAAISEQVRF,,,,,neo-epitope,IAAIREQVRF,Membrane-bound transcription factor site-2 protease,HLA-C*03:03,Cited reference,ELISA,0,2,0.0,10
1853234,IGDFGLATEK,,,,,neo-epitope,IGDFGLATVK,RAF proto-oncogene serine/threonine-protein kinase,HLA-A*11:01,Cited reference,ELISA,0,2,0.0,10
1853260,IKLIPGVSTT,,,,,neo-epitope,IKLIPGVSIT,PMS1 protein homolog 1,HLA-A*02:01,Cited reference,ELISA,0,2,0.0,10
1312765,IPVAIKTSP,,,,,neo-epitope,IPVAIKELREATSP,Epidermal growth factor receptor,HLA-B*35:01,Cited reference,ELISA,0,2,0.0,9
1853336,ISFENLDTA,,,,,neo-epitope,ISFENVDTA,Gamma-tubulin complex component,HLA-C*06:02,Cited reference,ELISA,0,2,0.0,9
1853353,ITYEYRPSK,,,,,neo-epitope,ITYEDRPSK,Interleukin-6 receptor subunit beta,HLA-A*30:01,Cited reference,ELISA,0,2,0.0,9
1853354,ITYEYRPSKA,,,,,neo-epitope,ITYEDRPSKA,Interleukin-6 receptor subunit beta,HLA-A*30:01,Cited reference,ELISA,0,2,0.0,10
1853371,KAEDLGMLLK,,,,,neo-epitope,KAEDRGMLLK,Transcription activator BRG1,HLA-A*11:01,Cited reference,ELISA,0,2,0.0,10
1853435,KIPVAITSPK,,,,,neo-epitope,KIPVAIKELREATSPK,Epidermal growth factor receptor,HLA-A*11:02,Cited reference,ELISA,0,2,0.0,10
1853452,KLIPGVSTT,,,,,neo-epitope,KLIPGVSIT,PMS1 protein homolog 1,HLA-A*02:01,Cited reference,ELISA,0,2,0.0,9
1863999,KLSPQQDAGV,,,,,neo-epitope,KLSPQQDAGG,G-protein coupled receptor family C group 5 member D,HLA-A*02:01,MHC binding prediction,ELISA,0,2,0.0,10
1087578,KLVVVGACGV,,,,,neo-epitope,KLVVVGAGGV,GTP-binding protein GEM,HLA-A*02:01,Cited reference,ELISA,0,2,0.0,10
175610,KLVVVGAGGV,5.0,14.0,GTPase KRas,GTP-binding protein GEM,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,3,0.0,10
1853508,KPPKAKPSPTY,,,,,neo-epitope,KPPKAKPASTV,Phosphatidylinositol 3-kinase regulatory subunit beta,HLA-B*07:02,Cited reference,ELISA,0,2,0.0,11
1861765,KQAKVVNPPI,30.0,39.0,alternative protein DHX40 [Homo sapiens],,,,,HLA-B*27:02,MHC binding prediction,ELISPOT,0,2,0.0,10
1714247,KQSVSPPV,,,,,neo-epitope,KQSVSPPI,TBC1 domain family member 9B,HLA-A*02:06,Cited reference,ELISPOT,0,2,0.0,8
1853526,KSAVLASNSQF,,,,,neo-epitope,KSAVLVSNSQF,Tubulin delta chain,HLA-B*57:01,Cited reference,ELISA,0,2,0.0,11
1853536,KSSPFTAAA,,,,,neo-epitope,KSSPFSAAA,Endothelial transcription factor GATA-2,HLA-C*15:02,Cited reference,ELISA,0,2,0.0,9
1853540,KTKPVHSSL,,,,,neo-epitope,KTKPVLSSL,Mediator of RNA polymerase II transcription subunit 12,HLA-B*15:27,Cited reference,ELISA,0,2,0.0,9
1312922,KTSPKANKEI,,,,,neo-epitope,KELREATSPKANKEI,Epidermal growth factor receptor,HLA-B*57:01,Cited reference,ELISA,0,2,0.0,10
1853541,KTSSGLYVFR,,,,,neo-epitope,KTSSGLYIFR,Breast cancer type 2 susceptibility protein,HLA-A*31:01,Cited reference,ELISA,0,2,0.0,10
1853556,KWIHCFNDV,,,,,neo-epitope,KWIQCFNDV,Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas,HLA-A*24:02,Cited reference,ELISA,0,2,0.0,9
1853569,LAECKDSLL,,,,,neo-epitope,LAECKGSLL,Androgen receptor,HLA-C*08:01,Cited reference,ELISA,0,2,0.0,9
1087605,LDYEGGTVTF,493.0,502.0,Tripartite motif-containing protein 26,Tripartite motif-containing protein 26,,,,HLA-B*15:01,MHC binding prediction,ELISPOT,0,2,0.0,10
1853632,LEFENKQAL,,,,,neo-epitope,SEFENKQAL,Serine-protein kinase ATM,HLA-B*40:01,Cited reference,ELISA,0,2,0.0,9
1853672,LGPMGGSLTL,,,,,neo-epitope,LGPMGGGLTL,Histone-lysine N-methyltransferase 2A,HLA-B*51:01,Cited reference,ELISA,0,2,0.0,10
1853678,LGSLHSGTAK,,,,,neo-epitope,LGFLHSGTAK,Cellular tumor antigen p53,HLA-A*11:01,Cited reference,ELISA,0,2,0.0,10
1853717,LKHPFTLMY,,,,,neo-epitope,LKHPFILMY,Dual specificity mitogen-activated protein kinase kinase 4,HLA-C*12:02,Cited reference,ELISA,0,2,0.0,9
1853757,LLGGNSFEV,,,,,neo-epitope,LLGRNSFEV,Cellular tumor antigen p53,HLA-A*02:06,Cited reference,ELISA,0,2,0.0,9
1853870,LPEPDKMLVAV,,,,,neo-epitope,LPEQDKMLVAV,High affinity nerve growth factor receptor,HLA-B*51:01,Cited reference,ELISA,0,2,0.0,11
1853999,LVRRSRTYSL,,,,,neo-epitope,LVRRSRTDSL,Insulin receptor substrate 2,HLA-B*07:02,Cited reference,ELISA,0,2,0.0,10
753264,LYPELIASI,139.0,147.0,Probable C-mannosyltransferase DPY19L4,Probable C-mannosyltransferase DPY19L4,,,,HLA-A*24:02,Single allele present,ELISPOT,0,2,0.0,9
40944,LYSDPADYF,227.0,235.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*24:02,MHC binding assay,ELISA,0,2,0.0,9
1854029,MASVDNPLM,,,,,neo-epitope,MASVDNPHV,Epidermal growth factor receptor,HLA-B*15:11,Cited reference,ELISA,0,2,0.0,9
1854086,MMMWDCWHA,,,,,neo-epitope,MMMRDCWHA,Fibroblast growth factor receptor 2,HLA-A*02:01,Cited reference,ELISA,0,2,0.0,9
1854087,MMMWDCWHAV,,,,,neo-epitope,MMMRDCWHAV,Fibroblast growth factor receptor 2,HLA-A*02:01,Cited reference,ELISA,0,2,0.0,10
1854092,MMWDCWHAV,,,,,neo-epitope,MMRDCWHAV,Fibroblast growth factor receptor 2,HLA-A*02:01,Cited reference,ELISA,0,2,0.0,9
1854098,MNLRPILTI,,,,,neo-epitope,MNRRPILTI,Cellular tumor antigen p53,HLA-B*52:01,Cited reference,ELISA,0,2,0.0,9
1854099,MNLRPILTII,,,,,neo-epitope,MNRRPILTII,Cellular tumor antigen p53,HLA-B*52:01,Cited reference,ELISA,0,2,0.0,10
1854110,MQLMPFGCL,,,,,neo-epitope,TQLMPFGCL,Epidermal growth factor receptor,HLA-A*02:06,Cited reference,ELISA,0,2,0.0,9
1862022,MRNSFAHSL,131.0,139.0,Baculoviral IAP repeat-containing protein 2,Baculoviral IAP repeat-containing protein 2,,,,HLA-B*27:05,MHC binding prediction,ELISPOT,0,2,0.0,9
1854156,NLLGGNSFEVR,,,,,neo-epitope,NLLGRNSFEVR,Cellular tumor antigen p53,HLA-A*33:01,Cited reference,ELISA,0,2,0.0,11
1854158,NLNKHRRYK,,,,,neo-epitope,NLNKHRRYE,Protein sidekick-2,HLA-A*11:01,Cited reference,ELISA,0,2,0.0,9
1854172,NPLMCRLLGI,,,,,neo-epitope,NPHVCRLLGI,Epidermal growth factor receptor,HLA-A*02:01,Cited reference,ELISA,0,2,0.0,10
1854206,NYICNSSCM,,,,,neo-epitope,NYMCNSSCM,Cellular tumor antigen p53,HLA-C*07:02,Cited reference,ELISA,0,2,0.0,9
1862142,PYKDFIATL,183.0,191.0,Prostatic acid phosphatase precursor,Prostatic acid phosphatase,,,,HLA-A*24:02,MHC binding assay,ELISA,0,2,0.0,9
1854402,QEIQILKAL,,,,,neo-epitope,REIQILKAL,Tyrosine-protein kinase JAK3,HLA-B*40:01,Cited reference,ELISA,0,2,0.0,9
1854425,QINITAVAHV,,,,,neo-epitope,QINITAVAQV,Integrin alpha-8,HLA-A*02:06,Cited reference,ELISA,0,2,0.0,10
1854449,QLIMQLMPF,,,,,neo-epitope,QLITQLMPF,Epidermal growth factor receptor,HLA-A*02:06,Cited reference,ELISA,0,2,0.0,9
1854459,QLWVDSTPL,,,,,neo-epitope,QLWVDSTPP,Cellular tumor antigen p53,HLA-B*39:01,Cited reference,ELISA,0,2,0.0,9
1854472,QQEIQILKAL,,,,,neo-epitope,QREIQILKAL,Tyrosine-protein kinase JAK3,HLA-B*40:01,Cited reference,ELISA,0,2,0.0,10
1854493,QVVKGDPPL,,,,,neo-epitope,QVVKGDPPQ,Dual specificity mitogen-activated protein kinase kinase 4,HLA-C*03:03,Cited reference,ELISA,0,2,0.0,9
1393320,QVWNPSFCFK,,,,,neo-epitope,QVWKPSFCFK,Synaptopodin,HLA-A*11:02,MHC binding prediction,ELISPOT,0,2,0.0,10
1854500,RAILLGAEEK,,,,,neo-epitope,LAKLLGAEEK,Epidermal growth factor receptor,HLA-A*11:01,Cited reference,ELISA,0,2,0.0,10
1854506,RASKARLPV,,,,,neo-epitope,RASKALLPV,Aquaporin-12B,HLA-B*08:01,Cited reference,ELISA,0,2,0.0,9
1397978,RATIVPEL,,,,,neo-epitope,RATIDPEL,Muskelin,HLA-C*03:04,MHC binding prediction,ELISPOT,0,2,0.0,8
1854510,RDFQQEIQIL,,,,,neo-epitope,RDFQREIQIL,Tyrosine-protein kinase JAK3,HLA-A*24:02,Cited reference,ELISA,0,2,0.0,10
1854513,RFKDIFQEM,,,,,neo-epitope,RFKDIFQEI,Isocitrate dehydrogenase [NADP] cytoplasmic,HLA-C*14:02,Cited reference,ELISA,0,2,0.0,9
1854529,RILKVTEFKK,,,,,neo-epitope,RILKETEFKK,Epidermal growth factor receptor,HLA-A*11:01,Cited reference,ELISA,0,2,0.0,10
1854553,RLPVGAYEV,,,,,neo-epitope,LLPVGAYEV,Aquaporin-12B,HLA-A*02:01,Cited reference,ELISA,0,2,0.0,9
1854560,RLSISFENL,,,,,neo-epitope,RLSISFENV,Gamma-tubulin complex component,HLA-A*02:01,Cited reference,ELISA,0,2,0.0,9
1854564,RLSSSSSSK,,,,,neo-epitope,RLSSSSSSE,Bromodomain-containing protein 3,HLA-A*11:01,Cited reference,ELISA,0,2,0.0,9
1854589,RRASKARLP,,,,,neo-epitope,RRASKALLP,Aquaporin-12B,HLA-C*06:02,Cited reference,ELISA,0,2,0.0,9
1066453,RYYVGHKGKF,10.0,19.0,Protein mago nashi homolog 2,Protein mago nashi homolog,,,,HLA-A*24:02,Single allele present,ELISA,0,3,0.0,10
1854630,SEITKQEKDF,,,,,neo-epitope,SEITEQEKDF,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",HLA-B*44:03,Cited reference,ELISA,0,2,0.0,10
1075663,SESIKKKVL,307.0,315.0,Melanoma-associated antigen C2,Melanoma-associated antigen C2,,,,HLA-B*44:03,MHC binding prediction,ELISPOT,0,2,0.0,9
1852340,SFPGIYDAL,704.0,712.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*24:02,MHC binding assay,ELISA,0,2,0.0,9
1854641,SGLYVFRNER,,,,,neo-epitope,SGLYIFRNER,Breast cancer type 2 susceptibility protein,HLA-A*31:01,Cited reference,ELISA,0,2,0.0,10
1087723,SILEQMRRK,283.0,291.0,Septin-9,Septin-9,,,,HLA-A*11:01,MHC binding prediction,ELISPOT,0,2,0.0,9
1854664,SISFENLDTA,,,,,neo-epitope,SISFENVDTA,Gamma-tubulin complex component,HLA-A*02:01,Cited reference,ELISA,0,2,0.0,10
1854680,SLEFENKQAL,,,,,neo-epitope,SSEFENKQAL,Serine-protein kinase ATM,HLA-B*40:01,Cited reference,ELISA,0,2,0.0,10
1854756,SPWATSSHL,,,,,neo-epitope,Proto-oncogene tyrosine-protein kinase receptor Ret,,HLA-B*07:02,Cited reference,ELISA,0,2,0.0,9
1393465,SQMEELPSV,,,,,neo-epitope,SEMEELPSV,,HLA-A*02:06,MHC binding prediction,ELISPOT,0,2,0.0,9
1854770,SSADHPGASK,,,,,neo-epitope,SSAEHPGASK,Microphthalmia-associated transcription factor,HLA-A*11:01,Cited reference,ELISA,0,2,0.0,10
1854773,SSCMGGMNLR,,,,,neo-epitope,SSCMGGMNRR,Cellular tumor antigen p53,HLA-A*11:01,Cited reference,ELISA,0,2,0.0,10
1075703,SSPGCQPPA,529.0,537.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-B*07:02,MHC binding prediction,ELISPOT,0,2,0.0,9
427487,STDPQHHAY,745.0,753.0,Chondroitin sulfate proteoglycan 4,Chondroitin sulfate proteoglycan 4,,,,HLA-A*01:01,MHC binding prediction,ELISPOT,0,2,0.0,9
1854798,STYMIQKAV,,,,,neo-epitope,STYMIQIAV,Proto-oncogene tyrosine-protein kinase ROS,HLA-A*32:01,Cited reference,ELISA,0,2,0.0,9
1854807,SVSFGTVYK,,,,,neo-epitope,SGSFGTVYK,RAF proto-oncogene serine/threonine-protein kinase,HLA-A*33:03,Cited reference,ELISA,0,2,0.0,9
1862468,SYKHEQVYI,96.0,104.0,Prostatic acid phosphatase precursor,Prostatic acid phosphatase,,,,HLA-A*24:02,MHC binding assay,ELISA,0,2,0.0,9
1862477,TALPQSILLF,,,,,neo-epitope,TALPRSILLF,Fidgetin,HLA-B*35:01,MHC binding prediction,ELISPOT,0,2,0.0,10
1854826,TDFGRAILL,,,,,neo-epitope,TDFGLAKLL,Epidermal growth factor receptor,HLA-B*50:01,Cited reference,ELISA,0,2,0.0,9
1854827,TDFGRAKLL,,,,,neo-epitope,TDFGLAKLL,Epidermal growth factor receptor,HLA-B*37:01,Cited reference,ELISA,0,6,0.0,9
1393506,TISKLYIPK,,,,,neo-epitope,IISKLYIPK,Ankyrin repeat domain-containing protein 36A,HLA-A*11:02,MHC binding prediction,ELISA,0,2,0.0,9
1854856,TIYVFEIRAR,,,,,neo-epitope,TIYVFQIRAR,Ephrin type-A receptor 3,HLA-A*11:01,Cited reference,ELISA,0,2,0.0,10
1854912,TPITMTLPF,,,,,neo-epitope,TPITMTFPF,Olfactory receptor 2T4,HLA-B*07:02,Cited reference,ELISA,0,2,0.0,9
1854921,TQGSAAELI,,,,,neo-epitope,TQGSTAELI,Neurofibromin,HLA-A*24:02,Cited reference,ELISA,0,2,0.0,9
1854935,TSSGLYVFR,,,,,neo-epitope,TSSGLYIFR,Breast cancer type 2 susceptibility protein,HLA-A*31:01,Cited reference,ELISA,0,2,0.0,9
1862576,TTLFHTFYEL,,,,,neo-epitope,TTLFHTFYDL,NLR family CARD domain-containing protein 4,HLA-A*24:02,MHC binding prediction,ELISPOT,0,2,0.0,10
1854953,TYQVSYGFR,,,,,neo-epitope,TYQGSYGFR,Cellular tumor antigen p53,HLA-A*31:01,Cited reference,ELISA,0,2,0.0,9
1087765,VADINDHAP,133.0,141.0,Protocadherin-16,Protocadherin-16,,,,HLA-C*03:03,MHC binding prediction,ELISPOT,0,2,0.0,9
1087767,VCRPLHYPLL,131.0,140.0,Olfactory receptor 2T3,Olfactory receptor 2T3,,,,HLA-C*07:02,MHC binding prediction,ELISPOT,0,2,0.0,10
1854988,VETDAAQPAV,,,,,neo-epitope,VETDAAQAAV,Cyclin-dependent kinase 13,HLA-B*40:01,Cited reference,ELISA,0,2,0.0,10
1855059,VLMGAVALGA,,,,,neo-epitope,VLTGAVALGA,Bcl-2-like protein 2 (Fragment),HLA-A*02:01,Cited reference,ELISA,0,2,0.0,10
1855060,VLMGAVALGAL,,,,,neo-epitope,VLTGAVALGAL,Bcl-2-like protein 2 (Fragment),HLA-A*02:01,Cited reference,ELISA,0,2,0.0,11
1393566,VLWHVTYWV,,,,,neo-epitope,VLWHVRYWV,Taste receptor type 2 member 46,HLA-A*02:01,MHC binding prediction,ELISA,0,2,0.0,9
1855075,VMASVDNPL,,,,,neo-epitope,VMASVDNPH,Epidermal growth factor receptor,HLA-A*02:01,Cited reference,ELISA,0,2,0.0,9
1066254,VQLIMQLMPF,,,,,neo-epitope,VQLITQLMPF,Epidermal growth factor receptor,HLA-A*02:06,Cited reference,ELISA,0,2,0.0,10
1855143,VVRHCPHHER,,,,,neo-epitope,VVRRCPHHER,Cellular tumor antigen p53,HLA-A*33:03,Cited reference,ELISA,0,2,0.0,10
1855144,VVTEVFLLA,,,,,neo-epitope,GVTEVFLLA,Olfactory receptor 5L2,HLA-A*02:06,Cited reference,ELISA,0,2,0.0,9
1393605,WQLEFLQPL,,,,,neo-epitope,RQLEFLQPL,Carbohydrate sulfotransferase 3,HLA-A*02:06,MHC binding prediction,ELISPOT,0,2,0.0,9
1862730,WTNCILHEY,,,,,neo-epitope,WTNRILHEY,Uncharacterized protein (Fragment),HLA-A*66:01,MHC binding prediction,ELISPOT,0,2,0.0,9
1855185,YEYRPSKAPSF,,,,,neo-epitope,YEDRPSKAPSF,Interleukin-6 receptor subunit beta,HLA-B*13:01,Cited reference,ELISA,0,2,0.0,11
74567,YLAPGPVTA,,,,,analog,YLEPGPVTA,Melanocyte protein PMEL,HLA-A*02:01,MHC binding assay,ELISA,0,2,0.0,9
534529,YLEPAPVTA,,,,,analog,YLEPGPVTA,Melanocyte protein PMEL,HLA-A*02:01,MHC binding assay,ELISA,0,2,0.0,9
1075853,YLHARLREL,462.0,470.0,Melanoma antigen preferentially expressed in tumors,Melanoma antigen preferentially expressed in tumors,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,0,2,0.0,9
1855229,YMPGGDLVKL,,,,,neo-epitope,YMPGGDLVNL,Rho-associated protein kinase 2,HLA-A*02:06,Cited reference,ELISA,0,2,0.0,10
546632,YSDHQPSGPYY,402.0,412.0,Transcription factor SOX-10,Transcription factor SOX-10,,,,HLA-A*01:01,MHC binding prediction,ELISPOT,0,3,0.0,11
1855249,YTAPGIVEI,,,,,neo-epitope,DTAPGIVEI,Otoancorin,HLA-C*03:03,Cited reference,ELISA,0,2,0.0,9
1398129,YVSEKDVISAK,,,,,neo-epitope,YVSEKDVTSAK,"Leucine-rich PPR motif-containing protein, mitochondrial",HLA-A*68:01,MHC binding prediction,ELISPOT,0,2,0.0,11
1855254,YYILDKKEHFK,,,,,neo-epitope,YYILEIRKSTS,Proto-oncogene tyrosine-protein kinase ROS,HLA-A*33:01,Cited reference,ELISA,0,2,0.0,11
155,AAGIGILTV,27.0,35.0,Melanoma antigen recognized by T-cells 1,Melanoma antigen recognized by T-cells 1,,,,HLA-A*02:01,MHC binding assay,ELISA,1,14,0.9285714285714286,9
785,ADVEFCLSL,316.0,324.0,Tyrosinase precursor,Tyrosinase,,,,HLA-B*44:03,MHC binding prediction,ELISPOT,1,2,0.5,9
1309173,AEHSLQVAY,,,,,neo-epitope,AEHSLQVAH,Vesicle-trafficking protein SEC22c (Fragment),HLA-B*44:03,T cell assay -Mismatched MHC molecules,ELISA,1,2,1.0,9
1594803,AGQHIAKSLF,,,,,neo-epitope,AGQHIAKSPF,Filamin-A,HLA-B*44:02,MHC binding prediction,ELISPOT,1,2,0.5,10
1310262,AIDAALTFV,,,,,neo-epitope,AIDAALTSV,Nuclear pore membrane glycoprotein 210,HLA-A*02:01,MHC binding assay,ELISA,1,2,0.5,9
1852506,AIKESPKANK,,,,,neo-epitope,AIKELREATSPKANK,Epidermal growth factor receptor,HLA-A*11:01,Cited reference,ELISPOT,1,3,0.6666666666666666,10
1312125,AIKTSPKANK,,,,,neo-epitope,AIKELREATSPKANK,Epidermal growth factor receptor,HLA-A*03:01,Cited reference,ELISA,1,4,0.75,10
1089142,AILALLPAL,105.0,113.0,prostate stem cell antigen [Homo sapiens],Prostate stem cell antigen,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,1.0,9
1087455,AIMPSSPPL,513.0,521.0,Transcription factor COE4,Transcription factor COE4,,,,HLA-B*15:01,MHC binding prediction,ELISPOT,1,2,0.5,9
1069080,ALDPHSGHFV,,,,,neo-epitope,ARDPHSGHFV,Cyclin-dependent kinase 4,HLA-A*02:01,Single allele present,ELISPOT,1,2,0.5,10
2489,ALDVYNGLL,299.0,307.0,Prostatic acid phosphatase precursor,Prostatic acid phosphatase,,,,HLA-A*02:01,Cited reference,ELISA,1,1,1.0,9
530809,ALEPGPVTA,,,,,analog,YLEPGPVTA,Melanocyte protein PMEL,HLA-A*02:01,Cited reference,ELISA,1,2,0.5,9
442279,ALFDIESKV,711.0,719.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,3,1.0,9
858753,ALIHHNTYL,,,,,neo-epitope,ALIHHNTHL,Receptor tyrosine-protein kinase erbB-2,HLA-A*02:01,Single allele present,ELISA,1,8,1.0,9
1338254,ALIRFLQQL,,,,,analog,ALIRILQQL,Protein Vpr,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
2644,ALIRILQQL,59.0,67.0,Protein Vpr,Protein Vpr,,,,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1338259,ALIRMLQQL,,,,,analog,ALIRILQQL,Protein Vpr,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1338267,ALIRWLQQL,,,,,analog,ALIRILQQL,Protein Vpr,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1338268,ALIRYLQQL,,,,,analog,ALIRILQQL,Protein Vpr,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
2684,ALLAGLVSLL,490.0,499.0,Tyrosinase precursor,Tyrosinase,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5,10
1861000,ALLMAGLAL,7.0,15.0,prostate stem cell antigen [Homo sapiens],Prostate stem cell antigen,,,,HLA-A*02:01,Single allele present,ELISA,1,5,0.8,9
1861001,ALLPALGLL,108.0,116.0,prostate stem cell antigen [Homo sapiens],Prostate stem cell antigen,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5,9
1862836,ALLPALGLLL,99.0,108.0,Prostate stem cell antigen,Prostate stem cell antigen,,,,HLA-A*02:01,Single allele present,ELISA,1,2,0.5,10
2779,ALNFPGSQK,87.0,95.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-A*11:01,MHC binding prediction,ELISPOT,1,2,1.0,9
1312161,ALNSEALSV,,,,,neo-epitope,ALNS,Transmembrane protease serine 2 (Fragment),HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0,9
1312162,ALNSEALSVV,,,,,neo-epitope,ALNS,Transmembrane protease serine 2 (Fragment),HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0,10
1861006,ALQPAAAIL,99.0,107.0,prostate stem cell antigen [Homo sapiens],Prostate stem cell antigen,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0,9
1861007,ALQPGTALL,5.0,13.0,Prostate stem cell antigen,Prostate stem cell antigen,,,,HLA-A*02:01,Single allele present,ELISA,1,3,0.6666666666666666,9
1334552,ALSYLVSFQR,,,,,neo-epitope,ALSYLVSFQT,,HLA-A*11:02,Single allele present,ELISPOT,1,2,1.0,10
1334553,ALSYLVSFQT,207.0,216.0,Zinc finger protein 878,,,,,HLA-A*11:02,Single allele present,ELISPOT,1,1,1.0,10
1870854,ALYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
858762,ALYGFVPVL,,,,,neo-epitope,ALYGSVPVL,Neutral alpha-glucosidase AB,HLA-A*02:01,Single allele present,ELISA,1,3,1.0,9
3146,AMLDLLKSV,664.0,672.0,Proto-oncogene DBL,Proto-oncogene DBL,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0,9
3147,AMLGTHTMEV,177.0,186.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5,10
1336387,AMPFSIFYPM,,,,,neo-epitope,AMPFSIFYRM,Proton channel OTOP1,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0,10
742497,APARLERRHSA,,,,,neo-epitope,ALARLERRHSA,Kinesin-like protein KIF16B,HLA-B*07:02,MHC binding prediction,ELISA,1,2,1.0,11
1398835,AQCPDVLV,,,,,neo-epitope,AQCPDVVV,Gem-associated protein 2,HLA-A*02:06,MHC binding prediction,ELISPOT,1,1,1.0,8
1309667,ASILAYLVV,38.0,46.0,P2X5a,P2X purinoceptor,,,,HLA-C*15:02,MHC binding prediction,ELISPOT,1,1,1.0,9
1087463,ASMPSSPPL,,,,,neo-epitope,AIMPSSPPL,Transcription factor COE4,HLA-B*15:01,MHC binding prediction,ELISPOT,1,3,0.6666666666666666,9
1334554,ASSYISPEK,272.0,280.0,Melanoma antigen preferentially expressed in tumors,Melanoma antigen preferentially expressed in tumors,,,,HLA-A*25:01,MHC binding prediction,ELISPOT,1,2,0.5,9
1334556,ATSPASASK,,,,,neo-epitope,ATSPASAS,Nuclear receptor subfamily 4 group A member 1,HLA-A*11:01,MHC binding prediction,ELISPOT,1,1,1.0,9
1725684,AVEEVSLRK,290.0,298.0,nucleophosmin,Nucleophosmin,,,,HLA-A*11:01,MHC binding assay,ELISA,1,5,0.6,9
1334557,AVIKIRFFK,240.0,248.0,G-protein coupled receptor 143,G-protein coupled receptor 143,,,,HLA-A*25:01,MHC binding prediction,ELISPOT,1,2,0.5,9
1076140,AVMRWGMPL,,,,,neo-epitope,AVMRWGMPP,Chromodomain-helicase-DNA-binding protein 3,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0,9
1076141,AVMRWGMPP,1423.0,1431.0,Chromodomain-helicase-DNA-binding protein 3,Chromodomain-helicase-DNA-binding protein 3,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0,9
1336446,AVYHEIHIGYL,,,,,neo-epitope,AVYHEILIGYL,CREB-binding protein,HLA-A*02:05,MHC binding prediction,ELISPOT,1,1,1.0,11
77841,AYDFLYNYL,161.0,169.0,Dermatan-sulfate epimerase precursor,Dermatan-sulfate epimerase,,,,HLA-A*24:02,Cited reference,ELISA,1,2,1.0,9
77842,AYIDFEMKI,333.0,341.0,Squamous cell carcinoma antigen recognized by T-cells 3,Squamous cell carcinoma antigen recognized by T-cells 3,,,,HLA-A*24:02,Cited reference,ELISA,1,6,0.6666666666666666,9
1852184,AYINADSSI,448.0,456.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*24:02,MHC binding assay,ELISA,1,2,1.0,9
1334731,AYLEAIHDF,,,,,neo-epitope,AYLEAIHNF,AP-2 complex subunit sigma,HLA-A*24:02,MHC binding assay,ELISPOT,1,1,1.0,9
1334734,AYLEAIHKF,,,,,neo-epitope,AYLEAIHNF,AP-2 complex subunit sigma,HLA-A*24:02,MHC binding assay,ELISPOT,1,1,1.0,9
436735,AYLEAIHNF,79.0,87.0,AP-2 complex subunit sigma,AP complex subunit sigma,,,,HLA-A*24:02,MHC binding assay,ELISPOT,1,1,1.0,9
1334737,AYLEAIHYF,,,,,neo-epitope,AYLEAIHNF,AP-2 complex subunit sigma,HLA-A*24:02,MHC binding assay,ELISPOT,1,1,1.0,9
956331,AYRDLQTRK,,,,,neo-epitope,AYRDLQTRE,Protein NipSnap homolog 2,HLA-A*30:01,Single allele present,ELISA,1,1,1.0,9
1125043,CISSCNPNL,,,,,neo-epitope,CISSCNPNP,Transcription factor HIVEP2,HLA-A*02:01,MHC binding prediction,ELISA,1,1,1.0,9
1338286,CLAVEEVSL,288.0,296.0,nucleophosmin [Homo sapiens],Nucleophosmin,neo-epitope,Nucleophosmin,,HLA-A*02:01,MHC binding assay,ELISA,1,6,1.0,9
1074867,CLGQLSNA,,,,,neo-epitope,CLGQLSNV,Mothers against decapentaplegic homolog 4,HLA-A*02:01,Single allele present,ELISPOT,1,1,1.0,8
1066644,CLWGRLWQL,,,,,analog,CQWGRLWQL,WD repeat-containing protein 46,HLA-A*02:01,T cell assay -Mismatched MHC molecules,ELISA,1,6,1.0,9
1870864,CLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1083942,CMLGTYTQDF,91.0,100.0,calcitonin isoform CT preproprotein [Homo sapiens],Calcitonin,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,3,1.0,10
6671,CMTWNQMNL,235.0,243.0,Wilms tumor protein,Wilms tumor protein,,,,HLA-A*24:02,Cited reference,ELISPOT,1,1,1.0,9
858793,CMWGRLWQL,,,,,analog,CQWGRLWQL,WD repeat-containing protein 46,HLA-A*02:01,T cell assay -Mismatched MHC molecules,ELISA,1,7,1.0,9
858794,CQWGRLWQL,,,WD repeat-containing protein BING4,WD repeat-containing protein 46,,,,HLA-A*02:01,T cell assay -Mismatched MHC molecules,ELISA,1,5,1.0,9
1125052,CTIAVVNFL,,,,,neo-epitope,CTNAVVNFL,Enoyl-CoA delta isomerase 2,HLA-A*68:02,Cited reference,ELISA,1,1,1.0,9
1862858,CVDDSQDYYV,61.0,70.0,Prostate stem cell antigen,Prostate stem cell antigen,,,,HLA-A*02:01,Single allele present,ELISA,1,2,1.0,10
1399225,CVRVSGQGL,,,,,neo-epitope,RVRVSGQGL,Filamin-A,HLA-B*07:02,MHC binding prediction,ELISPOT,1,1,1.0,9
1860817,CYASGWGSI,152.0,160.0,Prostate-specific antigen precursor,Prostate-specific antigen,,,,HLA-A*24:02,MHC binding assay,ELISA,1,2,1.0,9
1130596,CYMEALAL,20.0,27.0,Inactive hydroxysteroid dehydrogenase-like protein 1,Inactive hydroxysteroid dehydrogenase-like protein 1,,,,HLA-C*14:03,MHC binding prediction,ELISPOT,1,2,0.5,8
1130597,CYMEAVAL,,,,,neo-epitope,CYMEALAL,Inactive hydroxysteroid dehydrogenase-like protein 1,HLA-C*14:03,MHC binding prediction,ELISPOT,1,6,0.8333333333333334,8
1063259,DANSFLQSV,,,,,neo-epitope,DANPFLQSV,Mediator of RNA polymerase II transcription subunit 15,HLA-B*51:01,T cell assay -Biological process measured,ELISA,1,1,1.0,9
1334560,DDIYPIDFY,,,,,neo-epitope,DDIYPIDFH,Intraflagellar transport protein 80 homolog,HLA-A*25:01,Single allele present,ELISPOT,1,2,0.5,9
1397639,DENITTIQF,,,,,neo-epitope,DENITTIQC,Adhesion G protein-coupled receptor A3,HLA-B*18:01,MHC binding prediction,ELISPOT,1,1,1.0,9
1852721,DEVFGSSRL,,,,,neo-epitope,DEVFRFFEA,SH3 and PX domain-containing protein 2A,HLA-B*40:01,Cited reference,ELISA,1,2,0.5,9
1852199,DFEVFFQRL,520.0,528.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*24:02,MHC binding assay,ELISA,1,2,0.5,9
77848,DFMIQGGDF,99.0,107.0,Peptidyl-prolyl cis-trans isomerase B,Peptidyl-prolyl cis-trans isomerase B,,,,HLA-A*24:02,Cited reference,ELISA,1,2,0.5,9
1334563,DHYAYSYYL,,,,,neo-epitope,DHYAYSYYP,Receptor-type tyrosine-protein phosphatase U,HLA-C*06:02,Single allele present,ELISPOT,1,4,0.5,9
1334564,DHYAYSYYP,775.0,783.0,Receptor-type tyrosine-protein phosphatase U,Receptor-type tyrosine-protein phosphatase U,,,,HLA-B*51:01,Single allele present,ELISPOT,1,2,1.0,9
1334758,DLDLKGPKV,4788.0,4796.0,neuroblast differentiation-associated protein AHNAK isoform X1 [Homo sapiens],Neuroblast differentiation-associated protein AHNAK,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,1.0,9
1870866,DLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1861152,DMKARQKALV,,,,,neo-epitope,DMKARQEALV,Protein FAM50B,HLA-B*08:01,MHC binding prediction,ELISPOT,1,1,1.0,10
1397653,DTVEYPYTSF,,,,,neo-epitope,DTVEDPYTSF,Cofilin-2,HLA-A*26:01,MHC binding prediction,ELISPOT,1,1,1.0,10
1711652,DYLRSVLEDF,488.0,497.0,Tyrosine-protein kinase Lck,Tyrosine-protein kinase Lck,,,,HLA-A*24:02,Cited reference,ELISA,1,8,0.5,10
1087493,DYMIHIIEKW,,,,,neo-epitope,DYMSHIIEKW,Heparan-sulfate 6-O-sulfotransferase 1,HLA-B*27:05,MHC binding prediction,ELISPOT,1,2,0.5,10
1711653,DYSARWNEI,93.0,101.0,Dermatan-sulfate epimerase,DUF4962 domain-containing protein (Fragment),,,,HLA-A*24:02,Cited reference,ELISA,1,4,0.5,9
1862872,DYYVGKKNI,67.0,75.0,Prostate stem cell antigen,Prostate stem cell antigen,,,,HLA-A*24:02,MHC binding prediction,ELISA,1,1,1.0,9
10987,EAAGIGILTV,26.0,35.0,melanoma antigen recognized by T-cells 1,Melanoma antigen recognized by T-cells 1,,,,HLA-A*02:01,MHC binding assay,ELISA,1,14,0.8571428571428571,10
11010,EADPTGHSY,161.0,169.0,Melanoma-associated antigen 1,Melanoma-associated antigen 1,,,,HLA-A*01:01,MHC binding prediction,ELISPOT,1,2,1.0,9
1075245,EEAAGIGIL,25.0,33.0,Melanoma antigen recognized by T-cells 1,Melanoma antigen recognized by T-cells 1,,,,HLA-B*18:01,Single allele present,ELISPOT,1,2,1.0,9
1556302,EEMEPLPVM,,,,,neo-epitope,EEMEPPPVM,Interleukin-27 receptor subunit alpha,HLA-B*44:03,MHC binding prediction,ELISPOT,1,1,1.0,9
1075251,EFTVSGNIL,125.0,133.0,Cancer/testis antigen 1,Cancer/testis antigen 1,,,,HLA-B*40:01,Single allele present,ELISPOT,1,2,1.0,9
1852827,EKTSSGLYVFR,,,,,neo-epitope,EKTSSGLYIFR,Breast cancer type 2 susceptibility protein,HLA-A*31:01,Cited reference,ELISA,1,2,0.5,11
12941,ELAGIGILTV,,,,,analog,EAAGIGILTV,Melanoma antigen recognized by T-cells 1,HLA-A*02:01,Cited reference,ELISA,1,20,1.0,10
1870874,ELYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1334567,ERIPLPPHLC,566.0,575.0,Prickle-like protein 3,Prickle planar cell polarity protein 3,,,,HLA-C*06:02,Single allele present,ELISPOT,1,1,1.0,10
1075267,ESITGSLGPLL,448.0,458.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-B*40:01,Single allele present,ELISPOT,1,2,1.0,11
14195,ESLFRAVITK,95.0,104.0,Melanoma-associated antigen 1,Melanoma-associated antigen 1,,,,HLA-A*11:01,MHC binding prediction,ELISPOT,1,2,0.5,10
1397689,EVADAATLTM,,,,,neo-epitope,EVADAAKLTM,Zinc finger FYVE domain-containing protein 9,HLA-A*26:01,MHC binding prediction,ELISPOT,1,1,1.0,10
14672,EVDPIGHLY,168.0,176.0,Melanoma-associated antigen 3,Melanoma-associated antigen 3,,,,HLA-A*01:01,MHC binding prediction,ELISPOT,1,3,0.6666666666666666,9
1309203,EVLPFFLFF,,,,,neo-epitope,EALPFFLFF,Kynurenine formamidase (Fragment),HLA-A*29:02,T cell assay -Mismatched MHC molecules,ELISA,1,2,0.5,9
1852892,EYCLKFTKL,188.0,196.0,STAGA complex 65 subunit gamma,STAGA complex 65 subunit gamma,,,,HLA-A*24:02,Cited reference,ELISA,1,2,1.0,9
735825,EYILSLEEL,298.0,306.0,glypican 3,Glypican-3,,,,HLA-A*24:02,Cited reference,ELISPOT,1,2,1.0,9
606702,EYYSKNLNSF,,,,,neo-epitope,EYYSKNLNSS,Protein MMS22-like,HLA-A*24:02,MHC binding prediction,ELISPOT,1,1,1.0,10
1311332,FAIADTAYV,,,,,neo-epitope,FASADTAYV,Brefeldin A-inhibited guanine nucleotide-exchange protein 2,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5,9
1309710,FARAHALMF,,,,,neo-epitope,FARAHPLMF,Semaphorin-3G,HLA-B*15:01,MHC binding prediction,ELISPOT,1,1,1.0,9
1309711,FARAHPLMF,407.0,415.0,Semaphorin-3G,Semaphorin-3G,,,,HLA-B*15:01,MHC binding prediction,ELISPOT,1,1,1.0,9
175795,FATGIGIITV,,,,,analog,EAAGIGILTV,Melanoma antigen recognized by T-cells 1,HLA-A*02:01,MHC binding assay,ELISA,1,11,0.8181818181818182,10
1066332,FEDKSVAYT,,,,,neo-epitope,FEDKTVAYT,Protein disulfide-isomerase A3,HLA-C*05:01,MHC binding prediction,ELISPOT,1,1,1.0,9
1309205,FFYLLDFTF,,,,,neo-epitope,FFYPLDFTF,"Thioredoxin-dependent peroxide reductase, mitochondrial",HLA-A*29:02,T cell assay -Mismatched MHC molecules,ELISA,1,1,1.0,9
1556306,FGLLGNILLVI,,,,,neo-epitope,FGLLGNILVVI,C-C chemokine receptor type 6,HLA-A*02:24,MHC binding prediction,ELISPOT,1,1,1.0,11
1087511,FICAIIVVV,,,,,neo-epitope,FIGAIIVVV,Podoplanin,HLA-B*27:05,MHC binding prediction,ELISPOT,1,2,0.5,9
1336681,FISEYCGEI,,,,,neo-epitope,FISEYCGEI,Histone-lysine N-methyltransferase EZH2,HLA-A*02:05,Single allele present,ELISPOT,1,1,1.0,9
1397284,FLAEHEYGL,,,,,neo-epitope,FLAEHDYGL,Protein virilizer homolog,HLA-A*02:01,Cited reference,ELISA,1,3,1.0,9
1084399,FLALSILVL,9.0,17.0,calcitonin isoform CT preproprotein [Homo sapiens],Calcitonin,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,3,1.0,9
1311336,FLAPLFLVLL,,,,,neo-epitope,FLAPLFMVLL,Transmembrane protein 161B,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5,10
1334806,FLFYPLDFT,,,,,neo-epitope,FFFYPLDFT,Peroxiredoxin-4,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5,9
1087516,FLGAGLFLYF,,,,,neo-epitope,FLGAGLFIYF,HLA class II histocompatibility antigen DR beta chain,HLA-B*27:05,MHC binding prediction,ELISPOT,1,2,0.5,10
437314,FLGPWPAAS,22.0,30.0,alpha-2-macroglobulin receptor-associated protein precursor,Alpha-2-macroglobulin receptor-associated protein,,,,HLA-A*02:01,Cited reference,ELISA,1,5,1.0,9
1391970,FLGYLILGV,11.0,19.0,Kallikrein-4,Kallikrein-4,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,3,1.0,9
858914,FLIYLDVSV,,,,,neo-epitope,FLTYLDVSV,WD repeat-containing protein 46,HLA-A*02:01,T cell assay -Mismatched MHC molecules,ELISA,1,4,1.0,9
1069534,FLLDEAIGL,,,,,neo-epitope,FLLDEANGL,Speckle-type POZ protein,HLA-A*02:01,Single allele present,ELISPOT,1,2,0.5,9
1310406,FLLDSCTKL,,,,,neo-epitope,SLLDSCTKL,T-complex protein 1 subunit delta,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0,9
1392802,FLLPSGMAL,,,,,neo-epitope,FSLPSGMAL,ATP-binding cassette sub-family A member 2,HLA-C*03:04,MHC binding prediction,ELISA,1,1,1.0,9
16859,FLPWHRLFL,207.0,215.0,Tyrosinase precursor,Tyrosinase,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,3,0.6666666666666666,9
1069539,FLQEVNVCGV,,,,,neo-epitope,FLQEVNVYGV,"Solute carrier family 27 (Fatty acid transporter), member 3, isoform CRA_d",HLA-A*02:03,MHC binding prediction,ELISPOT,1,1,1.0,10
16878,FLRGRAYGL,325.0,333.0,Epstein-Barr nuclear antigen 3,Epstein-Barr nuclear antigen 3,,,,HLA-A*80:01,Cited reference,ELISPOT,1,1,1.0,9
1863176,FLRNFSLML,29.0,37.0,TCR gamma alternate reading frame protein isoform 1,,,,,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1863177,FLRNFSLMV,,,,,analog,FLRNFSLML,,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
911002,FLSDHLYLV,,,,,neo-epitope,FLSDHPYLV,Hsp90 co-chaperone Cdc37-like 1,HLA-A*02:01,Single allele present,ELISPOT,1,11,0.6363636363636364,9
1311341,FLTAHSLPL,,,,,neo-epitope,FLTAHRLPL,Protoporphyrinogen oxidase,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5,9
175797,FLTGIGIITV,,,,,analog,EAAGIGILTV,Melanoma antigen recognized by T-cells 1,HLA-A*02:01,MHC binding assay,ELISA,1,8,1.0,10
1870883,FLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
453847,FLYPFLSHL,1045.0,1053.0,EMILIN-2,EMILIN-2,,,,HLA-A*02:01,Cited reference,ELISA,1,1,1.0,9
1310409,FMFVNSLLL,,,,,neo-epitope,SMFVNSLLL,WD repeat-containing protein 75,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0,9
858919,FMPDFDLHL,,,,,neo-epitope,SMPDFDLHL,Neuroblast differentiation-associated protein AHNAK,HLA-A*02:01,Cited reference,ELISPOT,1,8,1.0,9
1861339,FPKKIQMLA,,,,,neo-epitope,FPKEIQMLA,ATP-dependent RNA helicase DDX3X,HLA-B*56:01,MHC binding prediction,ELISPOT,1,1,1.0,9
1861340,FPQGLPNEY,,,,,neo-epitope,FPQGLPDEY,,HLA-B*35:01,MHC binding prediction,ELISPOT,1,1,1.0,9
444026,FPSLREAAL,294.0,302.0,Melanoma-associated antigen 1,Melanoma-associated antigen 1,,,,HLA-B*07:02,MHC binding prediction,ELISPOT,1,2,0.5,9
1713734,FQDSVRTT,,,,,neo-epitope,FQDSVRIT,Integrin alpha-1,HLA-A*02:06,Cited reference,ELISPOT,1,2,0.5,8
566252,FQDYIKSYL,460.0,468.0,Tyrosinase precursor,Tyrosinase,,,,HLA-C*05:01,Cited reference,ELISPOT,1,2,1.0,9
1141232,FQETHLPI,,,,,neo-epitope,FQETHKNNPI,Calpain-7,HLA-B*39:01,MHC binding prediction,ELISPOT,1,4,0.75,8
1852975,FTLMYEERAV,,,,,neo-epitope,FILMYEERAV,Dual specificity mitogen-activated protein kinase kinase 4,HLA-A*02:01,Cited reference,ELISA,1,2,0.5,10
18159,FVFLRNFSL,27.0,35.0,TCR gamma alternate reading frame protein isoform 1,,,,,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
735828,FVGEFFTDV,144.0,152.0,glypican 3,Glypican-3,,,,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1397711,FVSTSDIKSM,,,,,neo-epitope,FVSKSDIKSM,"3-oxoacyl-[acyl-carrier-protein] synthase, mitochondrial",HLA-C*03:04,MHC binding prediction,ELISPOT,1,2,0.5,10
1334821,FVTETPLEG,53.0,61.0,cyclin-dependent kinase inhibitor 1 isoform 1 [Homo sapiens],Cyclin-dependent kinase inhibitor 1,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,1.0,9
1334822,FVTETPLEV,,,,,neo-epitope,FVTETPLEG,Cyclin-dependent kinase inhibitor 1,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5,9
1400125,FVVPYMIYLL,,,,,neo-epitope,YVVPYMIHLL,Sister chromatid cohesion protein PDS5 homolog A,HLA-C*03:03,T cell assay -MHC subset identification,ELISPOT,1,1,1.0,10
1141640,FWYTHNLIF,,,,,neo-epitope,FWYTHNLFF,NADPH oxidase 4,HLA-C*14:03,MHC binding prediction,ELISPOT,1,4,0.75,9
18380,FYDPMFKYHL,565.0,574.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*24:02,MHC binding assay,ELISA,1,2,0.5,10
1074749,FYGKTILWF,,,,,neo-epitope,FYGKTIPWF,Damage-control phosphatase ARMT1,HLA-A*24:02,Single allele present,ELISA,1,2,0.5,9
1066337,FYNDIILMV,,,,,neo-epitope,FYNDIILTV,WD repeat-containing protein 63,HLA-C*06:02,MHC binding prediction,ELISPOT,1,1,1.0,9
1087526,GAQSWLWFV,,,,,neo-epitope,GAQSWLWFA,Teneurin-3,HLA-A*02:11,MHC binding prediction,ELISPOT,1,4,0.5,9
1870887,GAYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1870888,GCYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
742500,GEEDGAGGHSL,,,,,neo-epitope,GEEDGAGGHSP,ATP-dependent DNA helicase Q5,HLA-B*44:02,MHC binding prediction,ELISA,1,1,1.0,11
1870896,GFYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1870898,GGYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1870901,GIYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1334848,GLDGAVDMG,,,,,neo-epitope,GLDGAVDMG,Aldehyde dehydrogenase family 16 member A1,HLA-A*02:01,MHC binding assay,ELISPOT,1,4,0.5,9
1540503,GLEPTTMV,,,,,neo-epitope,GLEPTTTV,Paired box protein Pax-3,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0,8
1870911,GLFDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5,9
1078646,GLGKGTYGV,,,,,neo-epitope,GVGKGTYGV,WD repeat-containing protein 7,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0,9
606734,GLGPGFSSY,,,,,neo-epitope,GLGPGFSGY,Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1 protein,HLA-B*15:01,T cell assay -Biological process measured,ELISPOT,1,2,1.0,9
742501,GLLDEDFYA,,,,,neo-epitope,GPLDEDFYA,UDP-glucose:glycoprotein glucosyltransferase 2,HLA-A*02:01,MHC binding prediction,ELISA,1,1,1.0,9
1336794,GLLNSIWPL,,,,,neo-epitope,GLLNSTWPL,Protein FAM86C1,HLA-A*02:01,Single allele present,ELISPOT,1,1,1.0,9
1870918,GLLVHPQWV,,,,,analog,GVLVHPQWV,Prostate-specific antigen,HLA-A*02:01,Cited reference,ELISPOT,1,2,1.0,9
1392184,GLQLGVQAV,229.0,237.0,Serine protease hepsin,Serine protease hepsin,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0,9
1870929,GLYCGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1870930,GLYDAMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1870935,GLYDGAEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5,9
1870940,GLYDGGEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5,9
1870944,GLYDGLEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5,9
1870948,GLYDGMEAL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5,9
1870949,GLYDGMECL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1870952,GLYDGMEFL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1870953,GLYDGMEGL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5,9
1870954,GLYDGMEHA,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5,9
1870955,GLYDGMEHC,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1870958,GLYDGMEHF,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1870961,GLYDGMEHI,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
189401,GLYDGMEHL,254.0,262.0,melanoma-associated antigen 10 [Homo sapiens],Melanoma-associated antigen 10,,,,HLA-A*02:01,Cited reference,ELISPOT,1,3,1.0,9
1870963,GLYDGMEHM,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1870966,GLYDGMEHQ,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5,9
1870968,GLYDGMEHS,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5,9
1870969,GLYDGMEHT,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1870970,GLYDGMEHV,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1870973,GLYDGMEIL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1870975,GLYDGMELL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1870976,GLYDGMEML,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1870977,GLYDGMENL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5,9
1870978,GLYDGMEPL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5,9
1870979,GLYDGMEQL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1870980,GLYDGMERL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1870981,GLYDGMESL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5,9
1870982,GLYDGMETL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5,9
1870983,GLYDGMEVL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1870985,GLYDGMEYL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1870995,GLYDGMQHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1870999,GLYDGMVHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5,9
1871003,GLYDGPEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1871011,GLYDHMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5,9
1871012,GLYDIMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5,9
1871014,GLYDLMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1871017,GLYDPMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1871020,GLYDSMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1871021,GLYDTMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1871032,GLYMGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1871033,GLYNGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,2,0.5,9
1853076,GLYVFRNER,,,,,neo-epitope,GLYIFRNER,Breast cancer type 2 susceptibility protein,HLA-A*31:01,Cited reference,ELISA,1,2,0.5,9
126153,GMMRWCMPV,131.0,139.0,"peptidase, U32 family",,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0,9
1871042,GMYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1871044,GNYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1309759,GPWGFSHGA,311.0,319.0,Trinucleotide repeat-containing gene 6A protein,Trinucleotide repeat-containing gene 6A protein,,,,HLA-B*27:05,MHC binding prediction,ELISPOT,1,1,1.0,9
742502,GQFLTPNSH,,,,,neo-epitope,GQFLAPNSH,Transcription factor Dp-2,HLA-B*15:01,MHC binding prediction,ELISA,1,1,1.0,9
1309760,GQWGFSHGA,,,,,neo-epitope,GPWGFSHGA,Trinucleotide repeat-containing gene 6A protein,HLA-B*27:05,MHC binding prediction,ELISPOT,1,1,1.0,9
1871047,GQYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
844616,GRIAFFLKY,,,,,neo-epitope,GRIAFSLKY,Synaptotagmin-like protein 4,HLA-B*27:05,MHC binding assay,ELISA,1,2,0.5,9
1087536,GRKLFGTHF,,,,,neo-epitope,GRKLFGTPF,Terminal uridylyltransferase 4,HLA-B*27:05,MHC binding prediction,ELISPOT,1,3,0.6666666666666666,9
1087537,GRKLFGTPF,1258.0,1266.0,Terminal uridylyltransferase 4,Terminal uridylyltransferase 4,,,,HLA-B*27:05,MHC binding prediction,ELISPOT,1,2,0.5,9
1309762,GSILAYLVV,,,,,neo-epitope,ASILAYLVV,P2X purinoceptor,HLA-C*15:02,MHC binding prediction,ELISPOT,1,1,1.0,9
1871049,GSYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1334571,GTAAIQAHYK,199.0,208.0,Transcription factor SOX-10,Transcription factor SOX-10,,,,HLA-A*03:01,MHC binding prediction,ELISPOT,1,2,0.5,10
1397721,GTKKDVDVLK,,,,,neo-epitope,GTKEDVDVLK,Replication termination factor 2,HLA-A*03:01,MHC binding prediction,ELISPOT,1,2,0.5,10
1871050,GTYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1594980,GVADVLLYR,,,,,neo-epitope,GVADALLYR,"Cytochrome c oxidase subunit 7A2, mitochondrial",HLA-A*11:01,MHC binding prediction,ELISPOT,1,1,1.0,9
23214,GVYDGEEHSV,231.0,240.0,Melanoma-associated antigen B2,Melanoma-associated antigen B2,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5,10
1871052,GVYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
23503,GYYDAQKLL,298.0,306.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*24:02,MHC binding assay,ELISA,1,2,0.5,9
1594985,HDLGRLHSC,,,,,neo-epitope,HDLGRLHPC,"All-trans-retinol 13,14-reductase",HLA-B*37:01,T cell assay -Mismatched MHC molecules,ELISPOT,1,2,1.0,9
1336862,HEIHIGYL,,,,,neo-epitope,HEILIGYL,CREB-binding protein,HLA-B*40:01,Single allele present,ELISPOT,1,1,1.0,8
1336863,HEIHIGYLEY,,,,,neo-epitope,HEILIGYLEY,CREB-binding protein,HLA-B*40:01,Single allele present,ELISPOT,1,1,1.0,10
1336864,HEIHIGYLEYV,,,,,neo-epitope,HEILIGYLEYV,CREB-binding protein,HLA-B*40:01,Single allele present,ELISPOT,1,1,1.0,11
1336865,HESRTNTAI,,,,,neo-epitope,HESRTNTDI,Myocyte-specific enhancer factor 2B,HLA-B*40:01,Single allele present,ELISPOT,1,2,1.0,9
1336866,HESRTNTAIL,,,,,neo-epitope,HESRTNTDIL,Myocyte-specific enhancer factor 2B,HLA-B*40:01,Single allele present,ELISPOT,1,3,0.6666666666666666,10
1070225,HIAKSLFEV,,,,,neo-epitope,HIAKSPFEV,Filamin-A,HLA-A*02:01,Single allele present,ELISPOT,1,3,0.6666666666666666,9
1309769,HIHCLNPPL,472.0,480.0,chromodomain-helicase-DNA-binding protein 4,Chromodomain-helicase-DNA-binding protein 4,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0,9
1309770,HIHCVNPPL,,,,,neo-epitope,HIHCLNPPL,Chromodomain-helicase-DNA-binding protein 3,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0,9
1146659,HLLSVEYQI,,,,,neo-epitope,HLLSVGYQI,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5,9
1392898,HLNGLLREA,1668.0,1676.0,ranBP2-like and GRIP domain-containing protein 4,RanBP2-like and GRIP domain-containing protein 4,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5,9
1392899,HLNGLLREV,,,,,neo-epitope,HLNGLLREA,RanBP2-like and GRIP domain-containing protein 4,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5,9
1871055,HLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1125066,HMTEVVRHC,,,,,neo-epitope,HMTEVVRRC,Cellular tumor antigen p53,HLA-A*02:01,T cell assay -Mismatched MHC molecules,ELISPOT,1,3,1.0,9
742503,HQNPVTGLLL,,,,,neo-epitope,HQNPVTGLLP,"Phosphorylase b kinase regulatory subunit alpha, skeletal muscle isoform",HLA-B*38:01,MHC binding prediction,ELISA,1,1,1.0,10
1075374,HRRGSRSYV,190.0,198.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-C*06:02,Single allele present,ELISPOT,1,2,1.0,9
1594989,HSCVMASLR,,,,,neo-epitope,HPCVMASLR,"All-trans-retinol 13,14-reductase",HLA-A*68:01,Single allele present,ELISPOT,1,1,1.0,9
1400690,HSVSSAFKK,,,,,neo-epitope,HSVSSAFKN,Formin-2,HLA-A*03:01,MHC binding prediction,ELISPOT,1,1,1.0,9
1101093,HVKITDFGR,,,,,neo-epitope,HVKITDFGL,Receptor tyrosine-protein kinase erbB-2,HLA-A*31:01,Cited reference,ELISA,1,4,0.5,9
1101094,HVKITDFGRAK,,,,,neo-epitope,HVKITDFGLAK,Epidermal growth factor receptor,HLA-A*11:01,Cited reference,ELISA,1,3,0.6666666666666666,11
1714010,HYRKWIKDTI,248.0,257.0,Prostate-specific antigen precursor,Prostate-specific antigen,,,,HLA-A*24:02,MHC binding assay,ELISA,1,2,1.0,10
1711657,HYTNASDGL,208.0,216.0,Tyrosine-protein kinase Lck,Tyrosine-protein kinase Lck,,,,HLA-A*24:02,Cited reference,ELISA,1,4,0.5,9
1309777,IAMAVLYLA,,,,,neo-epitope,IAVAVLYLA,Cyclin-Q,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0,9
1853231,IFQEMFDKHYK,,,,,neo-epitope,IFQEIFDKHYK,"Isocitrate dehydrogenase [NADP], mitochondrial",HLA-A*33:01,Cited reference,ELISA,1,2,0.5,11
1871062,IFVELVNAL,170.0,178.0,Histone-lysine N-methyltransferase EZH2,Histone-lysine N-methyltransferase EZH2,,,,HLA-A*24:02,MHC binding assay,ELISA,1,1,1.0,9
1148341,IHSTAQIIL,152.0,160.0,Olfactory receptor 4C11,Olfactory receptor 4C11,,,,HLA-B*39:01,MHC binding prediction,ELISPOT,1,1,1.0,9
1148345,IHYTAQIIL,,,,,neo-epitope,IHSTAQIIL,Olfactory receptor 4C11,HLA-B*39:01,MHC binding prediction,ELISPOT,1,4,0.5,9
710791,IIDDRNREL,11.0,19.0,"peroxiredoxin 6, partial [Homo sapiens]",Peroxiredoxin-6,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5,9
1125072,ILCETCLIV,,,,,neo-epitope,ILCGTCLIV,PH domain leucine-rich repeat-containing protein phosphatase 1,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0,9
859010,ILDKVLVHL,,,,,neo-epitope,ILDKVLVHP,"ATP-dependent Clp protease proteolytic subunit, mitochondrial",HLA-A*02:01,Single allele present,ELISA,1,2,1.0,9
1067282,ILEYLTAEV,58.0,66.0,Histone H2A.Z,Histone H2A.Z,,,,HLA-A*02:01,Cited reference,ELISA,1,1,1.0,9
1861614,ILMHGLVSL,,,,,neo-epitope,YLMHGLVSL,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0,9
859018,ILTGLNYEV,,,,,neo-epitope,ILTGLNYEA,"Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating",HLA-A*02:01,Single allele present,ELISA,1,1,1.0,9
1310498,ILWIFSIYL,,,,,neo-epitope,ILWTFSIYL,ER lumen protein-retaining receptor 3,HLA-A*02:01,Single allele present,ELISA,1,2,1.0,9
1871066,ILYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
27469,IMDQVPFSV,,,,,neo-epitope,ITDQVPFSV,Melanocyte protein PMEL,HLA-A*02:01,MHC binding assay,ELISA,1,4,0.75,9
83735,IMLEGETKL,76.0,84.0,ssDNA-binding phosphoprotein,Protein I3,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0,9
1309219,IMQTLAGELY,,,,,neo-epitope,IMQTPAGELY,eIF-2-alpha kinase activator GCN1,HLA-A*29:02,T cell assay -Mismatched MHC molecules,ELISA,1,1,1.0,10
1309220,IMRTYTYEI,,,,,neo-epitope,IMRTYTYEK,Catenin beta-1 (Fragment),HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0,9
1309221,IMRTYTYEK,327.0,335.0,Catenin beta-1,Catenin beta-1,,,,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0,9
1087564,IPINPRRCL,,,,,neo-epitope,TPINPRRCL,Coatomer subunit gamma-2,HLA-B*07:02,MHC binding prediction,ELISPOT,1,2,0.5,9
1861631,IPLSDNTIF,,,,,neo-epitope,IPLSDNTIS,Protein FAM200A (Fragment),HLA-B*35:01,MHC binding prediction,ELISPOT,1,1,1.0,9
1312766,IPVAIKTSPK,,,,,neo-epitope,IPVAIKELREATSPK,Epidermal growth factor receptor,HLA-A*11:01,Cited reference,ELISA,1,4,0.75,10
1309784,ISLNNAVIEL,,,,,neo-epitope,ISSNNAVIEL,Protein kintoun,HLA-C*15:02,MHC binding prediction,ELISPOT,1,1,1.0,10
1309785,ISSNNAVIEL,589.0,598.0,Protein kintoun,Protein kintoun,,,,HLA-C*15:02,MHC binding prediction,ELISPOT,1,1,1.0,10
1853345,ITDFGRAKL,,,,,neo-epitope,ITDFGLAKL,Epidermal growth factor receptor,HLA-C*04:01,Cited reference,ELISA,1,4,0.75,9
28864,ITDQVPFSV,209.0,217.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,7,0.8571428571428571,9
28958,ITKKVADLVGF,102.0,112.0,Melanoma-associated antigen 1,Melanoma-associated antigen 1,,,,HLA-B*57:01,MHC binding prediction,ELISPOT,1,2,1.0,11
910592,ITSAIGILPV,,,,,analog,EAAGIGILTV,Melanoma antigen recognized by T-cells 1,HLA-A*02:01,Cited reference,ELISA,1,1,1.0,10
910593,ITSAIGVLFV,,,,,analog,EAAGIGILTV,Melanoma antigen recognized by T-cells 1,HLA-A*02:01,Cited reference,ELISA,1,1,1.0,10
910594,ITSAIGVLPI,,,,,analog,EAAGIGILTV,Melanoma antigen recognized by T-cells 1,HLA-A*02:01,Cited reference,ELISA,1,1,1.0,10
910595,ITSAIGVLPV,,,,,analog,EAAGIGILTV,Melanoma antigen recognized by T-cells 1,HLA-A*02:01,Cited reference,ELISA,1,1,1.0,10
910596,ITSGIGVLPV,,,,,analog,EAAGIGILTV,Melanoma antigen recognized by T-cells 1,HLA-A*02:01,Cited reference,ELISA,1,1,1.0,10
859044,IYKAPCENW,,,,,neo-epitope,IYKAPSENW,DNA (cytosine-5)-methyltransferase 1,HLA-A*24:02,MHC binding prediction,ELISPOT,1,2,1.0,9
1862892,KAQVSNEDCL,18.0,27.0,Prostate stem cell antigen,Prostate stem cell antigen,,,,HLA-A*24:02,MHC binding prediction,ELISA,1,1,1.0,10
1853378,KARLPVGAY,,,,,neo-epitope,KALLPVGAY,Aquaporin-12B,HLA-A*03:01,Cited reference,ELISA,1,2,0.5,9
451342,KASEKIFYV,41.0,49.0,Protein SSX2,Protein SSX2,,,,HLA-A*02:01,Cited reference,ELISPOT,1,2,1.0,9
1853397,KELLKHPFTL,,,,,neo-epitope,KELLKHPFIL,Dual specificity mitogen-activated protein kinase kinase 4,HLA-A*02:01,Cited reference,ELISA,1,2,0.5,10
619431,KHGDVITII,83.0,91.0,"cell proliferation antigen Ki-67, short form - human",Proliferation marker protein Ki-67,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,1.0,9
31235,KIFGSLAFL,369.0,377.0,HER2 receptor,Receptor protein-tyrosine kinase,,,,HLA-A*02:01,Cited reference,ELISA,1,2,1.0,9
859062,KIFSEVTLK,,,,,neo-epitope,KIFSEVTPK,NAD-dependent protein deacetylase sirtuin-2,HLA-A*03:01,MHC binding prediction,ELISPOT,1,1,1.0,9
859065,KILDAVVAQK,,,,,neo-epitope,KILDAVVAQE,116 kDa U5 small nuclear ribonucleoprotein component,HLA-A*03:01,MHC binding prediction,ELISPOT,1,1,1.0,10
1104681,KITDFGRAK,,,,,neo-epitope,KITDFGLAK,Epidermal growth factor receptor,HLA-A*11:01,Cited reference,ELISA,1,4,1.0,9
1334928,KLGDVITII,,,,,neo-epitope,KHGDVITII,Proliferation marker protein Ki-67,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5,9
846039,KLILWRGLK,,,,,neo-epitope,KPILWRGLK,Condensin-2 complex subunit G2,HLA-A*03:01,MHC binding assay,ELISA,1,2,0.5,9
1863998,KLKAIPTTL,,,,,neo-epitope,KLKAIPTTI,PH domain leucine-rich repeat-containing protein phosphatase 1,HLA-A*02:01,MHC binding prediction,ELISA,1,2,0.5,9
1861741,KLKFVTLVF,,,,,neo-epitope,ELKFVTLVF,Prostatic acid phosphatase,HLA-A*24:02,MHC binding prediction,ELISPOT,1,2,1.0,9
1070772,KLVVVGADGV,,,,,neo-epitope,KLVVVGAGGV,GTP-binding protein GEM,HLA-A*02:03,MHC binding prediction,ELISPOT,1,1,1.0,10
958663,KLVVVGAVGV,,,,,neo-epitope,KLVVVGAGGV,GTP-binding protein GEM,HLA-A*02:01,MHC binding prediction,ELISPOT,1,3,0.6666666666666666,10
1871084,KLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1595039,KPFCVLISL,,,,,neo-epitope,KPFRVLISL,Protein dopey-2,HLA-B*07:02,Cited reference,ELISPOT,1,2,0.5,9
1595041,KPSDTPRPVM,,,,,neo-epitope,KPPDTPRPVM,Histone-lysine N-methyltransferase 2C,HLA-B*07:02,Cited reference,ELISPOT,1,2,0.5,10
1714242,KQHGFASI,,,,,neo-epitope,KQHGFASF,Store-operated calcium entry-associated regulatory factor (Fragment),HLA-A*02:06,Cited reference,ELISPOT,1,2,0.5,8
1087593,KQWLVWLFL,,,,,neo-epitope,KQWLVWLLL,Protein-cysteine N-palmitoyltransferase HHAT,HLA-A*02:06,MHC binding prediction,ELISPOT,1,5,0.8,9
1087594,KQWLVWLLL,68.0,76.0,Protein-cysteine N-palmitoyltransferase HHAT,Protein-cysteine N-palmitoyltransferase HHAT,,,,HLA-A*02:06,MHC binding prediction,ELISPOT,1,3,0.6666666666666666,9
1334586,KRIPLPPHLC,,,,,neo-epitope,ERIPLPPHLC,Prickle planar cell polarity protein 3,HLA-C*06:02,Single allele present,ELISPOT,1,2,0.5,10
1671929,KRPIPIKYKAM,,,,,neo-epitope,KRLIPIKYKAM,Myeloid differentiation primary response protein MyD88,HLA-B*07:02,Single allele present,ELISA,1,1,1.0,11
1861775,KRRWSALVI,62.0,70.0,alternative protein DHX40 [Homo sapiens],,,,,HLA-B*27:02,MHC binding prediction,ELISPOT,1,1,1.0,9
1125082,KSPNPSTPC,,,,,neo-epitope,KSPNPSTPR,Ribosomal L1 domain-containing protein 1,HLA-C*01:02,Cited reference,ELISA,1,1,1.0,9
1595047,KSQREFVRR,,,,,neo-epitope,ESQREFVRR,Cytosolic iron-sulfur assembly component 3,HLA-A*31:01,T cell assay -Mismatched MHC molecules,ELISPOT,1,3,0.6666666666666666,9
33915,KTWGQYWQV,154.0,162.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-A*02:01,Cited reference,ELISA,1,2,1.0,9
1853543,KTYQVSYGFR,,,,,neo-epitope,KTYQGSYGFR,Cellular tumor antigen p53,HLA-A*31:01,Cited reference,ELISA,1,2,0.5,10
1079584,KVDPIGHVY,,,,,neo-epitope,EVDPIGHVY,Melanoma-associated antigen 6 (Fragment),HLA-A*30:02,MHC binding prediction,ELISPOT,1,1,1.0,9
1852274,KVETYKEQPL,110.0,119.0,Parathyroid hormone-related protein,Parathyroid hormone-related protein,,,,HLA-A*24:02,Single allele present,ELISA,1,2,1.0,10
1334589,KVFRGNKVK,207.0,215.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*11:01,MHC binding prediction,ELISPOT,1,2,0.5,9
859097,KVYEGVWKK,,,,,neo-epitope,EVYEGVWKK,Tyrosine-protein kinase ABL1,HLA-A*03:01,MHC binding assay,ELISPOT,1,6,0.6666666666666666,9
34344,KYADKIYSI,606.0,614.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*24:02,MHC binding assay,ELISA,1,2,0.5,9
34349,KYAGESFPGI,699.0,708.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*24:02,MHC binding assay,ELISA,1,2,1.0,10
1075431,KYDCFLHPF,291.0,299.0,Histone-lysine N-methyltransferase EZH2,Histone-lysine N-methyltransferase EZH2,,,,HLA-A*24:02,MHC binding assay,ELISA,1,1,1.0,9
1871089,KYKELTEQQL,243.0,252.0,Histone-lysine N-methyltransferase EZH2,Histone-lysine N-methyltransferase EZH2,,,,HLA-A*24:02,MHC binding assay,ELISA,1,1,1.0,10
1075435,KYVGIEREM,735.0,743.0,Histone-lysine N-methyltransferase EZH2,Histone-lysine N-methyltransferase EZH2,,,,HLA-A*24:02,MHC binding assay,ELISA,1,1,1.0,9
1087606,LDYEWGTVTF,,,,,neo-epitope,LDYEGGTVTF,Tripartite motif-containing protein 26,HLA-B*15:01,Single allele present,ELISPOT,1,2,0.5,10
1861840,LFRIKFKEPL,,,,,neo-epitope,LYRIKFKESF,"Cytochrome c oxidase subunit 4 isoform 1, mitochondrial",HLA-B*08:01,MHC binding prediction,ELISPOT,1,1,1.0,10
1334973,LFSTAEAAV,304.0,312.0,cyclin-G-associated kinase isoform X15 [Homo sapiens],Cyclin-G-associated kinase,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5,9
1714397,LIDDYGVEEV,,,,,neo-epitope,LIDDYGVEEE,Transcriptional activator protein Pur-alpha,HLA-A*02:06,Cited reference,ELISPOT,1,2,0.5,10
1066141,LIMQLMPFGCL,100.0,110.0,"Chain A, Epidermal Growth Factor Receptor",Receptor protein-tyrosine kinase,neo-epitope,LITQLMPFGCL,Epidermal growth factor receptor,HLA-A*02:01,MHC binding assay,ELISPOT,1,3,1.0,11
1085428,LLAALVQDYL,,,calcitonin,Calcitonin,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,3,1.0,10
1067642,LLALAAGLAV,8.0,17.0,Arylsulfatase A,Arylsulfatase A,,,,HLA-A*02:01,Single allele present,ELISA,1,1,1.0,10
1861874,LLALLMAGL,5.0,13.0,prostate stem cell antigen [Homo sapiens],Prostate stem cell antigen,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,3,0.6666666666666666,9
1862897,LLALLPALGL,,,prostate stem cell antigen,,,,,HLA-A*02:01,Single allele present,ELISA,1,2,1.0,10
1334592,LLAPGGNSM,131.0,139.0,Transcription factor SOX-2,Transcription factor SOX-2,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5,9
37113,LLAVLYCLL,2.0,10.0,Tyrosinase precursor,Tyrosinase,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5,9
1862898,LLCYSCKAQV,12.0,21.0,Prostate stem cell antigen,Prostate stem cell antigen,,,,HLA-A*02:01,Single allele present,ELISA,1,3,1.0,10
106609,LLDVAPLSL,393.0,401.0,Heat shock 70 kDa protein 1,Heat shock 70 kDa protein 1A,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0,9
37257,LLFGYPVYV,11.0,19.0,transcriptional activator Tax,,,,,HLA-A*02:01,Cited reference,ELISPOT,1,3,1.0,9
1309852,LLGCVMYTLL,,,,,neo-epitope,SLGCVMYTLL,Serine/threonine-protein kinase PLK3,HLA-A*02:11,MHC binding prediction,ELISPOT,1,2,0.5,10
1107872,LLHETDSAV,4.0,12.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*02:01,MHC binding assay,ELISA,1,3,0.6666666666666666,9
1071271,LLKAELVAGL,,,,,neo-epitope,LLKAVLVAGL,ATP-dependent RNA helicase DHX29,HLA-A*02:03,MHC binding prediction,ELISPOT,1,1,1.0,10
1853770,LLKHPFTLM,,,,,neo-epitope,LLKHPFILM,Dual specificity mitogen-activated protein kinase kinase 4,HLA-A*30:01,Cited reference,ELISA,1,2,0.5,9
106610,LLLLDVAPL,391.0,399.0,Heat shock 70 kDa protein 1,Heat shock 70 kDa protein 1A,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0,9
506786,LLLSAEPVPA,19.0,28.0,B-cell antigen receptor complex-associated protein beta chain isoform 1 precursor,B-cell antigen receptor complex-associated protein beta chain,,,,HLA-A*02:01,Cited reference,ELISA,1,1,1.0,10
1861892,LLLWGPGQL,115.0,123.0,prostate stem cell antigen [Homo sapiens],Prostate stem cell antigen,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5,9
1861893,LLPALGLLL,100.0,108.0,Prostate stem cell antigen,Prostate stem cell antigen,,,,HLA-A*02:01,Single allele present,ELISA,1,2,0.5,9
1871101,LLQERGVAYI,441.0,450.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*02:01,Cited reference,ELISA,1,1,1.0,10
37954,LLWSFQTSA,9.0,17.0,Tyrosinase precursor,Tyrosinase,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5,9
1871103,LLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1401631,LLYQELLPL,,,,,neo-epitope,LLYQEFLPL,Transformation/transcription domain-associated protein (Fragment),HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0,9
106611,LMGDKSENV,380.0,388.0,Heat shock 70 kDa protein 1,Heat shock 70 kDa protein 1A,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0,9
38060,LMLGEFLKL,,,,,analog,LTLGEFLKL,Baculoviral IAP repeat-containing protein 5,HLA-A*02:01,Not determined,ELISPOT,1,1,1.0,9
1393134,LMRDHMPPV,,,,,neo-epitope,LMRDHVPPV,Sodium-independent sulfate anion transporter,HLA-A*02:03,MHC binding prediction,ELISA,1,1,1.0,9
1861913,LPNEYAFVT,,,,,neo-epitope,LPDEYAFVT,,HLA-B*35:01,MHC binding prediction,ELISPOT,1,1,1.0,9
1861914,LPNEYAFVTT,,,,,neo-epitope,LPDEYAFVTT,,HLA-B*35:01,MHC binding prediction,ELISPOT,1,1,1.0,10
1080391,LQIEEEYQV,236.0,244.0,L protein,,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0,9
1861930,LRAAFFGKCF,,,,,neo-epitope,LRAASFGKCF,Vacuolar protein sorting-associated protein 16 homolog,HLA-B*27:05,MHC binding prediction,ELISPOT,1,1,1.0,10
1853910,LRILKVTEFK,,,,,neo-epitope,LRILKETEFK,Epidermal growth factor receptor,HLA-A*11:01,Cited reference,ELISA,1,2,0.5,10
1335005,LRSEGSPLV,1147.0,1155.0,proto-oncogene [Homo sapiens],Hepatocyte growth factor receptor,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,4,0.75,9
1401933,LRTKVYAEL,,,,,neo-epitope,LRTKVHAEL,T-complex protein 1 subunit zeta,HLA-B*27:05,MHC binding prediction,ELISPOT,1,1,1.0,9
568114,LSEKLERI,155.0,162.0,15 kDa selenoprotein,Selenoprotein F,,,,HLA-A*02:01,Cited reference,ELISA,1,1,1.0,8
1067709,LTLLGTLWGA,17.0,26.0,Protocadherin gamma-A6,Protocadherin gamma-A6,,,,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0,10
910612,LTSAIGVLPV,,,,,analog,EAAGIGILTV,Melanoma antigen recognized by T-cells 1,HLA-A*02:01,Cited reference,ELISA,1,1,1.0,10
1853980,LTSTVQLIM,,,,,neo-epitope,LTSTVQLIT,Epidermal growth factor receptor,HLA-B*35:01,Cited reference,ELISA,1,5,0.6,9
1871120,LVLAGGFFL,26.0,34.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*02:01,Cited reference,ELISA,1,1,1.0,9
1334606,LVRRTLLHA,26.0,34.0,IQ domain-containing protein F5,IQ domain-containing protein F5,,,,HLA-C*15:02,Single allele present,ELISPOT,1,1,1.0,9
1334607,LVRRTLLHV,,,,,neo-epitope,LVRRTLLHA,IQ domain-containing protein F5,HLA-C*15:02,Single allele present,ELISPOT,1,2,0.5,9
1714545,LYCESVHNF,213.0,221.0,Prostatic acid phosphatase precursor,Prostatic acid phosphatase,,,,HLA-A*24:02,MHC binding assay,ELISA,1,2,0.5,9
40868,LYNFTQIPHL,74.0,83.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*24:02,MHC binding assay,ELISA,1,2,0.5,10
1402151,LYNGMEHLI,,,,,neo-epitope,LYDGMEHLI,Melanoma-associated antigen 10,HLA-A*24:02,MHC binding prediction,ELISPOT,1,1,1.0,9
753263,LYPEFIASI,,,,,neo-epitope,LYPELIASI,Probable C-mannosyltransferase DPY19L4,HLA-A*24:02,Single allele present,ELISPOT,1,3,1.0,9
1313135,MALNSEALSV,,,,,neo-epitope,MALNS,Transmembrane protease serine 2 (Fragment),HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0,10
1067740,MCQWGRLWQL,,,WD repeat-containing protein BING4,WD repeat-containing protein 46,,,,HLA-A*02:01,T cell assay -Mismatched MHC molecules,ELISA,1,7,1.0,10
139171,MEIFIEVFSHF,1.0,11.0,Minor histocompatibility protein HMSD variant form,Minor histocompatibility protein HMSD variant form,,,,HLA-B*44:03,T cell assay -Mismatched MHC molecules,ELISA,1,2,1.0,11
544090,MEVDPIGHLY,167.0,176.0,Melanoma-associated antigen 3,Melanoma-associated antigen 3,,,,HLA-B*18:01,Cited reference,ELISPOT,1,4,1.0,10
41745,MIMQGGFSV,694.0,702.0,Proto-oncogene DBL,Proto-oncogene DBL,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0,9
41953,MLGTHTMEV,178.0,186.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5,9
1334611,MLICCCCTL,,,,,neo-epitope,LICCCCTL,Solute carrier family 12 member 4,HLA-A*02:10,MHC binding prediction,ELISPOT,1,1,1.0,9
753265,MLIGIPVYV,,,,,neo-epitope,MVIGIPVYV,E3 ubiquitin-protein ligase RNF19B,HLA-A*02:01,Single allele present,ELISPOT,1,1,1.0,9
1871124,MLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1332820,MPIEPGDIGC,,,,,neo-epitope,MPIEPGDIGY,Bombesin receptor-activated protein C6orf89,HLA-B*35:01,MHC binding assay,ELISPOT,1,1,1.0,10
859210,MQLMPFGCLL,102.0,111.0,"Chain A, Epidermal Growth Factor Receptor",Receptor protein-tyrosine kinase,neo-epitope,TQLMPFGCLL,Epidermal growth factor receptor,HLA-A*02:01,MHC binding assay,ELISPOT,1,4,1.0,10
1085695,MQLMPFGSLL,,,,,neo-epitope,TQLMPFGCLL,Epidermal growth factor receptor,HLA-A*02:01,MHC binding assay,ELISPOT,1,3,0.6666666666666666,10
1595127,MRMNQGVCC,,,,,neo-epitope,MRMSQGVCC,Liprin-alpha-4,HLA-B*39:06,T cell assay -Mismatched MHC molecules,ELISPOT,1,2,1.0,9
910618,MTSAIGILPV,,,,,analog,EAAGIGILTV,Melanoma antigen recognized by T-cells 1,HLA-A*02:01,Cited reference,ELISA,1,2,1.0,10
910619,MTSAIGVLPV,,,,,analog,EAAGIGILTV,Melanoma antigen recognized by T-cells 1,HLA-A*02:01,Cited reference,ELISA,1,1,1.0,10
753266,MVIGIPVYV,180.0,188.0,RNF19B protein,E3 ubiquitin-protein ligase RNF19B,,,,HLA-A*02:01,Single allele present,ELISPOT,1,1,1.0,9
1860851,MWVPVVFLTL,1.0,10.0,Prostate-specific antigen precursor,Prostate-specific antigen,,,,HLA-A*24:02,MHC binding assay,ELISA,1,2,0.5,10
1334612,NISEDVIFF,,,,,neo-epitope,NISEDVIFS,Importin-8,HLA-A*25:01,Single allele present,ELISPOT,1,2,0.5,9
1338547,NLVPFVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
133255,NLVPGVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1338548,NLVPHVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
44919,NLVPIVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
44920,NLVPMVATV,495.0,503.0,tegument protein pp65 [Human betaherpesvirus 5],65 kDa phosphoprotein,,,,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1338550,NLVPNVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1338551,NLVPPVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
135858,NLVPQVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1338552,NLVPRVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
135859,NLVPSVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
135860,NLVPTVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
135861,NLVPVVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1338553,NLVPWVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1338554,NLVPYVATV,,,,,analog,NLVPMVATV,65 kDa phosphoprotein,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1871130,NLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1337428,NTVILETLK,,,,,neo-epitope,NTDILETLK,Myocyte-specific enhancer factor 2B,HLA-A*11:02,Single allele present,ELISPOT,1,1,1.0,9
46581,NYARTEDFF,178.0,186.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*24:02,MHC binding assay,ELISA,1,2,0.5,9
1392357,PLTEYIQPV,268.0,276.0,Serine protease hepsin,Serine protease hepsin,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0,9
1871139,PLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
859283,PSDTRQMLFY,,,,,neo-epitope,PFDTRQMLFY,E3 ubiquitin-protein ligase TRIP12,HLA-A*01:01,Single allele present,ELISA,1,3,1.0,10
1334615,PVKNLPQM,537.0,544.0,"Beta-1,4-N-acetylgalactosaminyltransferase 3","Beta-1,4-N-acetylgalactosaminyltransferase 3",,,,HLA-B*51:01,Single allele present,ELISPOT,1,1,1.0,8
1334616,PVKNLPQV,,,,,neo-epitope,PVKNLPQM,"Beta-1,4-N-acetylgalactosaminyltransferase 3",HLA-B*51:01,Single allele present,ELISPOT,1,2,0.5,8
1125095,QCEEVARVL,,,,,neo-epitope,QCEEVARAL,Galactokinase,HLA-B*35:03,Cited reference,ELISA,1,1,1.0,9
1397966,QDVSVQVER,,,,,neo-epitope,QDVSVQVEM,Ankyrin repeat domain-containing protein 20B,HLA-A*68:01,MHC binding prediction,ELISPOT,1,2,0.5,9
1854400,QEECLWMAV,,,,,neo-epitope,QEECLGMAV,Tyrosine-protein kinase JAK2,HLA-B*40:02,Cited reference,ELISA,1,2,0.5,9
1715107,QIIHTYSNTV,,,,,neo-epitope,QIIHTDSNTV,BTB/POZ domain-containing protein 2,HLA-A*02:06,Cited reference,ELISPOT,1,2,0.5,10
1688151,QKRPIPIKYKAM,,,,,neo-epitope,QKRLIPIKYKAM,Myeloid differentiation primary response protein MyD88,HLA-B*07:02,Single allele present,ELISA,1,1,1.0,12
1854429,QKTYQVSYGFR,,,,,neo-epitope,QKTYQGSYGFR,Cellular tumor antigen p53,HLA-A*31:01,Cited reference,ELISA,1,2,0.5,11
857795,QLCDVMFYL,,,,,neo-epitope,QLRDVMFYL,BRCA1-associated protein,HLA-A*02:01,MHC binding prediction,ELISA,1,4,1.0,9
1862171,QLGEQCWTA,34.0,42.0,Prostate stem cell antigen,Prostate stem cell antigen,,,,HLA-A*02:01,Single allele present,ELISA,1,2,1.0,9
180706,QLLNSVLTL,248.0,256.0,uncharacterized protein KIAA1551,Retroelement silencing factor 1,,,,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0,9
1864045,QLQKANVLL,,,,,neo-epitope,QLQKANVRL,Villin-like protein,HLA-A*02:01,MHC binding prediction,ELISA,1,2,0.5,9
1367390,QLWQFLLEL,295.0,303.0,transcriptional regulator ERG isoform 2 [Homo sapiens],Erythroblast transformation-specific transcription factor ERG variant 10,,,,HLA-A*02:01,T cell assay -T cell subset identification,ELISPOT,1,2,1.0,9
1871144,QLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1391971,QMVEASLSV,95.0,103.0,Kallikrein-4,Kallikrein-4,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,1.0,9
51809,QPEWFRNVL,145.0,153.0,Polymerase basic protein 1,RNA-directed RNA polymerase catalytic subunit,,,,HLA-B*07:02,Cited reference,ELISPOT,1,1,1.0,9
1113688,QPSGIILDY,,,,,neo-epitope,QPNGIILDY,Ephrin type-B receptor 1,HLA-B*35:01,MHC binding prediction,ELISPOT,1,1,1.0,9
1556360,QSLFWSIFV,,,,,neo-epitope,QSLFWSIFG,Short transient receptor potential channel 4,HLA-A*69:01,MHC binding prediction,ELISPOT,1,1,1.0,9
1309261,QTNPVTLQY,,,,,neo-epitope,QTDPVTLQY,Helicase with zinc finger domain 2,HLA-A*29:02,T cell assay -Mismatched MHC molecules,ELISA,1,2,1.0,9
910623,QTSAIGILPV,,,,,analog,EAAGIGILTV,Melanoma antigen recognized by T-cells 1,HLA-A*02:01,Cited reference,ELISA,1,1,1.0,10
910624,QTSAIGVLPV,,,,,analog,EAAGIGILTV,Melanoma antigen recognized by T-cells 1,HLA-A*02:01,Cited reference,ELISA,1,1,1.0,10
52886,QYDPVAALF,331.0,339.0,pp65,65 kDa phosphoprotein,,,,HLA-A*24:02,Cited reference,ELISA,1,1,1.0,9
53036,QYSWFVNGTF,268.0,277.0,Carcinoembryonic antigen-related cell adhesion molecule 5 precursor,Carcinoembryonic antigen-related cell adhesion molecule 5,,,,HLA-A*24:02,Not determined,ELISPOT,1,1,1.0,10
1114008,RAKLLGAEEK,,,,,neo-epitope,LAKLLGAEEK,Receptor protein-tyrosine kinase,HLA-A*31:01,MHC binding prediction,ELISPOT,1,1,1.0,10
1114056,RATVAPRSL,,,,,neo-epitope,serine/threonine-protein kinase STK11 [Homo sapiens],,HLA-C*03:03,MHC binding prediction,ELISPOT,1,1,1.0,9
1852331,RAVSEHQLL,36.0,44.0,Parathyroid hormone-related protein,Parathyroid hormone-related protein,,,,HLA-A*24:02,Single allele present,ELISA,1,2,1.0,9
1334620,REEKIHDLAL,,,,,neo-epitope,EEKIHDLAL,Glutamine--fructose-6-phosphate aminotransferase [isomerizing] 2,HLA-B*40:01,MHC binding prediction,ELISPOT,1,1,1.0,10
1862219,REFDKIELAY,,,,,neo-epitope,REFDEIELAY,"Glutamate receptor ionotropic, NMDA 2B",HLA-B*41:02,MHC binding prediction,ELISPOT,1,1,1.0,10
1596760,RFLEYLPLRF,,,,,neo-epitope,RSLEYLPLRF,Dephospho-CoA kinase domain-containing protein,HLA-A*24:02,MHC binding prediction,ELISPOT,1,1,1.0,10
742510,RHDLPPYRVYL,,,,,neo-epitope,RHDLPPYRVHL,Cell cycle and apoptosis regulator protein 2,HLA-B*38:01,MHC binding prediction,ELISA,1,1,1.0,11
1854528,RILKVTEFK,,,,,neo-epitope,RILKETEFK,Epidermal growth factor receptor,HLA-A*11:01,Cited reference,ELISA,1,2,0.5,9
1862242,RIRAVGLLTV,52.0,61.0,prostate stem cell antigen [Homo sapiens],Prostate stem cell antigen,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0,10
54313,RIWSWLLGA,473.0,481.0,Tyrosinase precursor,Tyrosinase,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5,9
956443,RLARLALVL,17.0,25.0,Trophoblast glycoprotein,Trophoblast glycoprotein,,,,HLA-A*02:01,MHC binding assay,ELISA,1,4,1.0,9
1310769,RLDAVLMEV,,,,,neo-epitope,RPDAVLMEV,E3 ubiquitin-protein ligase MYLIP,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0,9
1854538,RLDPRMSTLQK,,,,,neo-epitope,SH3 and PX domain-containing protein 2A,,HLA-A*11:01,Cited reference,ELISA,1,2,0.5,11
1690645,RLFLGLAIK,,,,,neo-epitope,RLFPGLAIK,Kinesin-like protein KIF2C,HLA-A*03:01,MHC binding assay,ELISA,1,2,0.5,9
232216,RLPRIFCSC,639.0,647.0,melanocyte protein PMEL isoform 3 preproprotein [Homo sapiens],Melanocyte protein PMEL,,,,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0,9
1393358,RLRKRNEYR,,,,,neo-epitope,RLRKGNEYR,E3 ubiquitin-protein ligase TRIM68,HLA-A*31:01,MHC binding prediction,ELISA,1,1,1.0,9
1871154,RLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1391972,RMPTVLQCV,160.0,168.0,Kallikrein-4,Kallikrein-4,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,1.0,9
1595203,RPHHDQRSL,,,,,neo-epitope,RPHHDQRSS,Tau-tubulin kinase 2,HLA-B*07:02,Single allele present,ELISPOT,1,2,0.5,9
859339,RPHVPESAF,,,,,neo-epitope,GPHVPESAF,E3 ubiquitin-protein ligase UBR4,HLA-B*07:02,Single allele present,ELISPOT,1,1,1.0,9
1691013,RPIPIKYKA,,,,,neo-epitope,RLIPIKYKA,Myeloid differentiation primary response protein MyD88,HLA-B*07:02,Single allele present,ELISA,1,1,1.0,9
1691014,RPIPIKYKAM,,,,,neo-epitope,RLIPIKYKAM,Myeloid differentiation primary response protein MyD88,HLA-B*07:02,Single allele present,ELISA,1,5,0.6,10
55252,RPPIFIRRL,379.0,387.0,EBNA3A nuclear protein,Epstein-Barr nuclear antigen 3,,,,HLA-B*07:02,Cited reference,ELISPOT,1,1,1.0,9
458440,RPPITQSSL,382.0,390.0,RNA-binding protein 27,RNA-binding protein 27,,,,HLA-B*07:02,MHC binding assay,ELISPOT,1,1,1.0,9
1337717,RPRCLCTAV,,,,,neo-epitope,RPRCLRTAV,CREB-binding protein,HLA-B*07:02,Single allele present,ELISPOT,1,2,0.5,9
1852333,RSVEGLSRRL,25.0,34.0,Parathyroid hormone-related protein,Parathyroid hormone-related protein,,,,HLA-A*24:02,Single allele present,ELISA,1,2,1.0,10
1337753,RTAVYHEIHI,,,,,neo-epitope,RTAVYHEILI,CREB-binding protein,HLA-B*57:01,Single allele present,ELISPOT,1,2,1.0,10
1337757,RTNTAILETL,,,,,neo-epitope,RTNTDILETL,Myocyte-specific enhancer factor 2B,HLA-C*03:04,MHC binding prediction,ELISPOT,1,1,1.0,10
1337758,RTNTGILETLK,,,,,neo-epitope,RTNTDILETLK,Myocyte-specific enhancer factor 2B,HLA-A*03:02,MHC binding prediction,ELISPOT,1,2,0.5,11
1337759,RTNTVILETLK,,,,,neo-epitope,RTNTDILETLK,Myocyte-specific enhancer factor 2B,HLA-A*11:02,Single allele present,ELISPOT,1,1,1.0,11
1632362,RTQDAEFLK,,,,,neo-epitope,PTQDAEFLK,Paraneoplastic antigen-like protein 8A,HLA-A*11:01,Single allele present,ELISA,1,3,0.6666666666666666,9
1334624,RTSSTQQDNPK,,,,,neo-epitope,RSSSTQQDNPK,TRIO and F-actin-binding protein,HLA-A*11:01,Single allele present,ELISPOT,1,2,1.0,11
1334625,RTSSTQQDNPQ,355.0,365.0,TRIO and F-actin-binding protein,TRIO and F-actin-binding protein,,,,HLA-A*11:01,Single allele present,ELISPOT,1,1,1.0,11
1309278,RVCGPCSTY,,,,,neo-epitope,RVRGPCSTY,Phospholipid scramblase (Fragment),HLA-A*29:02,T cell assay -Mismatched MHC molecules,ELISA,1,1,1.0,9
179897,RVRFFFPSL,289.0,297.0,Melanoma-associated antigen 1,Melanoma-associated antigen 1,,,,HLA-B*07:02,Cited reference,ELISPOT,1,2,1.0,9
1087716,RVRVMAIYK,,,,,neo-epitope,RVRAMAIYK,Cellular tumor antigen p53,HLA-A*11:01,MHC binding prediction,ELISPOT,1,2,0.5,9
742513,RVSTLRVSL,,,,,neo-epitope,RVSTLRVSP,Guanine nucleotide-binding protein subunit beta-5,HLA-B*07:02,MHC binding prediction,ELISA,1,1,1.0,9
1337790,RVYISYLDCI,,,,,neo-epitope,RVYISYLDSI,CREB-binding protein,HLA-A*30:01,Single allele present,ELISPOT,1,2,1.0,10
767706,RYCNLEGPPI,133.0,142.0,"LY6K protein, partial [Homo sapiens]",Lymphocyte antigen 6K,,,,HLA-A*24:02,Cited reference,ELISPOT,1,1,1.0,10
545022,RYGSFSVTL,479.0,487.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-C*07:01,Single allele present,ELISPOT,1,2,1.0,9
1715353,RYLTQETNKV,102.0,111.0,Parathyroid hormone-related protein,Parathyroid hormone-related protein,,,,HLA-A*24:02,Single allele present,ELISA,1,2,1.0,10
1066452,RYYVGHKAKF,,,,,neo-epitope,RYYVGHKGKF,Protein mago nashi homolog,HLA-A*24:02,Single allele present,ELISA,1,6,0.5,10
56721,SACDVSVRV,464.0,472.0,Solute carrier family 45 member 3,Solute carrier family 45 member 3,,,,HLA-C*05:01,Not determined,ELISPOT,1,2,1.0,9
56722,SACDVSVRVV,464.0,473.0,Solute carrier family 45 member 3,Solute carrier family 45 member 3,,,,HLA-C*05:01,Not determined,ELISPOT,1,2,1.0,10
1334627,SADVEFCLSL,315.0,324.0,Tyrosinase precursor,Tyrosinase,,,,HLA-B*44:03,MHC binding prediction,ELISPOT,1,2,0.5,10
110702,SAFRCFIVY,55.0,63.0,E5 protein,,,,,HLA-B*15:01,Single allele present,ELISA,1,2,1.0,9
1125133,SCMGGMNWR,,,,,neo-epitope,SCMGGMNRR,Cellular tumor antigen p53,HLA-A*68:01,Cited reference,ELISA,1,1,1.0,9
1125137,SCSRAVPQV,,,,,neo-epitope,SCSRAIPQV,Cytoplasmic FMR1-interacting protein 1,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0,9
1334628,SEHGFGPSL,,,,,neo-epitope,SEHGFGP,Mitochondrial peptide methionine sulfoxide reductase,HLA-B*40:01,MHC binding prediction,ELISPOT,1,1,1.0,9
1334629,SEIISFKSL,,,,,neo-epitope,SEIISFKSM,Fasciculation and elongation protein zeta-1,HLA-B*40:01,MHC binding prediction,ELISPOT,1,1,1.0,9
57494,SEIWRDIDF,192.0,200.0,Tyrosinase precursor,Tyrosinase,,,,HLA-B*44:03,MHC binding prediction,ELISPOT,1,2,0.5,9
859441,SHETVIIEL,,,,,neo-epitope,SHETVTIEL,Small nuclear ribonucleoprotein Sm D1,HLA-B*38:01,MHC binding prediction,ELISPOT,1,1,1.0,9
1087722,SILEQMHRK,,,,,neo-epitope,SILEQMRRK,Septin-9,HLA-A*11:01,Single allele present,ELISPOT,1,4,0.5,9
1404434,SISCHVFCL,,,,,neo-epitope,SISCHVLCL,Protein mono-ADP-ribosyltransferase PARP10,HLA-A*02:06,MHC binding prediction,ELISPOT,1,2,1.0,9
545215,SLADTNSLAVV,570.0,580.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5,11
59278,SLLMWITQC,157.0,165.0,NY-ESO-1 protein,Cancer/testis antigen 1,,,,HLA-A*02:01,Cited reference,ELISPOT,1,25,0.96,9
59283,SLLMWITQV,,,,,analog,SLLMWITQC,Cancer/testis antigen 1,HLA-A*02:01,Not determined,ELISA,1,7,1.0,9
1392429,SLLSGDWVL,191.0,199.0,Serine protease hepsin,Serine protease hepsin,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0,9
1309582,SLMEQIPHL,,,Cytoskeleton-associated protein 2,,,,,HLA-A*02:01,MHC binding prediction,ELISA,1,1,1.0,9
1393438,SLPMKNFPV,,,,,neo-epitope,SLPTKNFPV,IQ domain-containing protein E,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0,9
1074628,SLSKILDTV,904.0,912.0,breast cancer antigen NY-BR-1,Ankyrin repeat domain-containing protein 30A,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0,9
1871162,SLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1542524,SLYDLDIEA,,,,,neo-epitope,SSYDLDIEA,Protocadherin beta-15,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0,9
1087726,SMACVGFFL,,,,,neo-epitope,IMACVGFFL,Killer cell immunoglobulin-like receptor 2DS4,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5,9
1334632,SMYLPGAEV,275.0,283.0,Transcription factor SOX-2,Transcription factor SOX-2,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5,9
1337923,SRTNTAILETL,,,,,neo-epitope,SRTNTDILETL,Myocyte-specific enhancer factor 2B,HLA-B*40:01,Single allele present,ELISPOT,1,1,1.0,11
1337924,SRTNTAILEV,,,,,neo-epitope,SRTNTDILEV,Myocyte-specific enhancer factor 2B,HLA-C*06:02,MHC binding prediction,ELISPOT,1,1,1.0,10
1398002,SSAAAPFPL,,,,,neo-epitope,SSAAAPFPH,Ran-binding protein 9,HLA-C*03:04,MHC binding prediction,ELISPOT,1,2,0.5,9
1334636,SSEDDGFFLGE,556.0,566.0,Prickle-like protein 3,Prickle planar cell polarity protein 3,,,,HLA-A*11:01,Single allele present,ELISPOT,1,1,1.0,11
1334637,SSEDDGFFLGK,,,,,neo-epitope,SSEDDGFFLGE,Prickle planar cell polarity protein 3,HLA-A*11:01,Single allele present,ELISPOT,1,2,0.5,11
1334638,SSEIISFKSL,,,,,neo-epitope,SSEIISFKSM,Fasciculation and elongation protein zeta-1,HLA-B*40:01,MHC binding prediction,ELISPOT,1,1,1.0,10
1595249,SSYTGFANK,,,,,neo-epitope,SNYTGFANK,Kinesin-like protein KIF26B,HLA-A*11:01,Single allele present,ELISPOT,1,6,0.5,9
1854796,STPLPGTRVR,,,,,neo-epitope,STPPPGTRVR,Cellular tumor antigen p53,HLA-A*11:01,Cited reference,ELISA,1,2,0.5,10
1854797,STVQLIMQL,,,,,neo-epitope,STVQLITQL,Epidermal growth factor receptor,HLA-C*15:02,Cited reference,ELISA,1,3,0.6666666666666666,9
911532,SVLENFTIFL,,,,,neo-epitope,SVLENFTILL,Transcriptional enhancer factor TEF-1,HLA-A*02:01,Single allele present,ELISA,1,1,1.0,10
1068341,SVLWLGALGL,50.0,59.0,Uncharacterized protein C20orf141,Uncharacterized protein C20orf141,,,,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0,10
742515,SYMIMEIEL,,,,,neo-epitope,SSMIMEIEL,F-box only protein 21,HLA-C*14:02,MHC binding prediction,ELISA,1,1,1.0,9
78024,SYTRLFLIL,899.0,907.0,Dermatan-sulfate epimerase precursor,Dermatan-sulfate epimerase,,,,HLA-A*24:02,Cited reference,ELISA,1,2,0.5,9
1309291,TEDEHFEFY,,,,,neo-epitope,TEDEHFEFH,Targeting protein for Xklp2,HLA-B*44:03,T cell assay -Mismatched MHC molecules,ELISA,1,1,1.0,9
1334644,TIGVDFALK,41.0,49.0,Ras-related protein Rab-38,Ras-related protein Rab-38,,,,HLA-A*25:01,MHC binding prediction,ELISPOT,1,2,0.5,9
1335269,TLAEDLNLL,,,,,neo-epitope,TSAEDLNLL,DNA damage-binding protein 1,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5,9
545697,TLDEKVAEL,140.0,148.0,Melanoma-associated antigen C2,Melanoma-associated antigen C2,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5,9
859505,TLDWLLQTPK,,,,,neo-epitope,TLGWLLQTPK,GPNMB protein,HLA-A*03:01,MHC binding prediction,ELISPOT,1,1,1.0,10
1393512,TLFSALWAL,,,,,neo-epitope,TLFSALRAL,Cytoplasmic dynein 1 heavy chain 1,HLA-A*02:06,MHC binding prediction,ELISA,1,2,1.0,9
1073444,TLMSAMTNL,112.0,120.0,Prostatic acid phosphatase precursor,Prostatic acid phosphatase,,,,HLA-A*02:01,Cited reference,ELISA,1,1,1.0,9
742517,TLWCSPIKV,,,,,neo-epitope,TPWCSPIKV,Sushi repeat-containing protein SRPX,HLA-A*02:01,Single allele present,ELISA,1,6,1.0,9
1871173,TLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1309294,TLYSLTLLY,,,,,neo-epitope,TLYSLTPLY,Centromere protein L,HLA-A*29:02,T cell assay -Mismatched MHC molecules,ELISA,1,2,1.0,9
449299,TMLARLASA,21.0,29.0,Chondroitin sulfate proteoglycan 4,Chondroitin sulfate proteoglycan 4,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,2,0.5,9
1542850,TMSLYDLDIEA,,,,,neo-epitope,TMSSYDLDIEA,Protocadherin beta-15,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0,11
1854914,TPLPGTRVRA,,,,,neo-epitope,TPPPGTRVRA,Cellular tumor antigen p53,HLA-B*54:01,Cited reference,ELISA,1,2,0.5,10
65748,TPRVTGGGAM,417.0,426.0,tegument protein pp65 [Human betaherpesvirus 5],65 kDa phosphoprotein,,,,HLA-B*07:02,Cited reference,ELISPOT,1,3,1.0,10
1338005,TPTDVTARHL,,,,,neo-epitope,TPTDVTAIHL,G1/S-specific cyclin-D3,HLA-B*35:01,Single allele present,ELISPOT,1,1,1.0,10
1334049,TPTVPSSSF,,,,,neo-epitope,TPTVPSGSF,Alstrom syndrome protein 1,HLA-B*35:01,MHC binding assay,ELISPOT,1,1,1.0,9
859524,TQLMPFGCLL,790.0,799.0,Epidermal growth factor receptor precursor,Epidermal growth factor receptor,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,1.0,10
1086794,TQLMPFGSLL,,,,,neo-epitope,TQLMPFGCLL,Epidermal growth factor receptor,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0,10
1335294,TSAEDLNLL,24.0,32.0,Xeroderma Pigmentosum Group E Complementing protein [Homo sapiens],DNA damage-binding protein 1,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5,9
1087759,TSDYLSQSY,,,,,neo-epitope,TSDYVSQSY,Ubiquitin carboxyl-terminal hydrolase 47,HLA-A*01:01,MHC binding prediction,ELISPOT,1,2,0.5,9
729016,TSIANLPKL,,,,,neo-epitope,TSIANLPKL,Acidic leucine-rich nuclear phosphoprotein 32 family member A,HLA-A*02:01,MHC binding assay,ELISPOT,1,4,0.5,9
942779,TVAELVQFL,79.0,87.0,Melanoma-associated antigen F1,Melanoma-associated antigen F1,,,,HLA-C*06:02,MHC binding prediction,ELISPOT,1,1,1.0,9
67308,TYACFVSNL,652.0,660.0,Carcinoembryonic antigen-related cell adhesion molecule 5 precursor,Carcinoembryonic antigen-related cell adhesion molecule 5,,,,HLA-A*24:02,Not determined,ELISPOT,1,1,1.0,9
606965,TYLPSAWNF,,,,,neo-epitope,TYLPSAWNS,PR domain zinc finger protein 10 (Fragment),HLA-A*24:02,T cell assay -Biological process measured,ELISPOT,1,2,1.0,9
606966,TYLPSAWNFF,,,,,neo-epitope,TYLPSAWNSF,PR domain zinc finger protein 10 (Fragment),HLA-A*24:02,MHC binding prediction,ELISPOT,1,1,1.0,10
67474,TYSVSFDSL,624.0,632.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*24:02,MHC binding assay,ELISA,1,2,1.0,9
67475,TYSVSFDSLF,624.0,633.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*24:02,MHC binding assay,ELISA,1,2,1.0,10
1087764,VADINDHAL,,,,,neo-epitope,VADINDHAP,Protocadherin-16,HLA-C*03:03,MHC binding prediction,ELISPOT,1,3,0.6666666666666666,9
1864059,VARLSSKSV,,,,,neo-epitope,VARLSSKSV,Tumor necrosis factor receptor superfamily member 6,HLA-C*03:04,MHC binding prediction,ELISA,1,2,0.5,9
1854977,VDNPLMCRL,,,,,neo-epitope,VDNPHVCRL,Epidermal growth factor receptor,HLA-B*37:04,Cited reference,ELISA,1,2,0.5,9
1334647,VEWLGRCIL,,,,,neo-epitope,EWLGRCIL,Chondroitin sulfate synthase 2,HLA-B*40:01,MHC binding prediction,ELISPOT,1,1,1.0,9
1852391,VFELANSIVL,584.0,593.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*24:02,MHC binding assay,ELISA,1,2,0.5,10
1068511,VIIKPLVWV,215.0,223.0,Serum amyloid P-component,Serum amyloid P-component,,,,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0,9
1855033,VKITDFGRAK,,,,,neo-epitope,VKITDFGLAK,Epidermal growth factor receptor,HLA-A*11:01,Cited reference,ELISA,1,2,0.5,10
1862947,VLAGGFFLL,27.0,35.0,Glutamate carboxypeptidase 2,Glutamate carboxypeptidase 2,,,,HLA-A*02:01,MHC binding prediction,ELISA,1,2,1.0,9
1309304,VLAMAIYKQ,,,,,neo-epitope,VRAMAIYKQ,Cellular tumor antigen p53,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0,9
907518,VLAVFIKAV,10.0,18.0,Immunoglobulin J chain,Immunoglobulin J chain,,,,HLA-A*02:01,Cited reference,ELISA,1,1,1.0,9
859563,VLENFTIFLV,,,,,neo-epitope,VLENFTILLV,Transcriptional enhancer factor TEF-1,HLA-A*02:01,Single allele present,ELISA,1,1,1.0,10
1862948,VLLALLMAGL,4.0,13.0,prostate stem cell antigen [Homo sapiens],Prostate stem cell antigen,,,,HLA-A*02:01,Single allele present,ELISA,1,2,1.0,10
742518,VLLGVKLFGV,,,,,neo-epitope,VLLGVKLSGV,Collagen alpha-1(XVIII) chain,HLA-A*02:01,Single allele present,ELISA,1,4,1.0,10
1086925,VLLQAGSLHA,16.0,25.0,calcitonin isoform CT preproprotein [Homo sapiens],Calcitonin,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,3,1.0,10
1075782,VLNGTVHPV,700.0,708.0,ATP-binding cassette sub-family B member 5,ATP-binding cassette sub-family B member 5,,,,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1391977,VLQCVNVSV,164.0,172.0,Kallikrein-4,Kallikrein-4,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,3,1.0,9
1391978,VLVHPQWVL,59.0,67.0,Kallikrein-4,Kallikrein-4,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,1.0,9
1310905,VLWDYVYQL,,,,,neo-epitope,LLWDYVYQL,Transcription factor ETV7,HLA-A*02:01,MHC binding assay,ELISA,1,2,1.0,9
1310906,VLWDYVYQLL,,,,,neo-epitope,LLWDYVYQLL,Transcription factor ETV7,HLA-A*02:01,MHC binding assay,ELISA,1,2,1.0,10
1871190,VLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1082754,VMLEGEQEA,,,,,neo-epitope,VMLEGEQEE,Programmed cell death protein 7,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0,9
1082755,VMLEGEQEE,375.0,383.0,Programmed cell death protein 7,Programmed cell death protein 7,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0,9
1405954,VQIISCQY,,,,,neo-epitope,VQIIPCQY,Mediator of RNA polymerase II transcription subunit 13,HLA-A*30:02,T cell assay -MHC subset identification,ELISPOT,1,2,1.0,8
1083076,VQLEEEYEV,,,,,neo-epitope,VQLEEEYED,Unconventional myosin-XVIIIa,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,1.0,9
1309307,VRAMAIYKQ,157.0,165.0,Cellular tumor antigen p53,Cellular tumor antigen p53,,,,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0,9
1862676,VRTLLSQVNK,,,,,neo-epitope,VRTPLSQVNK,Citron Rho-interacting kinase,HLA-B*27:05,MHC binding prediction,ELISPOT,1,1,1.0,10
1335345,VSDEGGSPI,,,,,neo-epitope,VSDEGGSPI,Cyclin-G-associated kinase,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5,9
1595342,VSKILPSTW,,,,,neo-epitope,VSKTLPSTW,Clathrin interactor 1,HLA-B*57:01,MHC binding prediction,ELISPOT,1,2,1.0,9
1862691,VTEKLQPTY,,,,,neo-epitope,VTEKLQLTY,Integrin alpha-9,HLA-A*01:01,MHC binding prediction,ELISPOT,1,1,1.0,9
1123008,VTIGPRLLL,,,,,neo-epitope,VTIGPRLFL,Neuron navigator 3,HLA-C*03:03,MHC binding prediction,ELISPOT,1,1,1.0,9
859592,VVMSWAPPV,,,,,neo-epitope,VVLSWAPPV,Fibronectin type III domain-containing protein 3B,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5,9
1393591,VVVPCEPPEV,,,,,neo-epitope,VVVPYEPPEV,Cellular tumor antigen p53,HLA-A*02:01,MHC binding prediction,ELISPOT,1,3,0.6666666666666666,10
1393592,VVVPYEPPEV,216.0,225.0,Cellular tumor antigen p53,Cellular tumor antigen p53,,,,HLA-A*02:01,MHC binding prediction,ELISPOT,1,3,0.6666666666666666,10
1311524,VYALIAGATL,,,,,neo-epitope,VCALIAGATL,Protein phosphatase 1F,HLA-A*02:01,MHC binding prediction,ELISPOT,1,3,0.6666666666666666,10
78068,VYDYNCHVDL,109.0,118.0,Squamous cell carcinoma antigen recognized by T-cells 3,Squamous cell carcinoma antigen recognized by T-cells 3,,,,HLA-A*24:02,Cited reference,ELISA,1,6,0.8333333333333334,10
1075826,VYFFLPDHL,,,,,neo-epitope,Melanocyte protein Pmel 17 precursor,,HLA-A*24:02,Cited reference,ELISPOT,1,3,1.0,9
473138,VYGIRLEHF,56.0,64.0,kinetochore protein Nuf2,Kinetochore protein Nuf2,,,,HLA-A*24:02,Single allele present,ELISPOT,1,2,1.0,9
1338137,VYHEIHIGYL,,,,,neo-epitope,VYHEILIGYL,CREB-binding protein,HLA-B*40:01,Single allele present,ELISPOT,1,1,1.0,10
606993,VYQYTFPDF,,,,,neo-epitope,VYQYTSPDF,Insulin-induced gene 1 protein,HLA-A*24:02,T cell assay -Biological process measured,ELISPOT,1,2,1.0,9
606994,VYQYTFPDFL,,,,,neo-epitope,VYQYTSPDFL,Insulin-induced gene 1 protein,HLA-A*24:02,MHC binding prediction,ELISPOT,1,1,1.0,10
1087792,VYRPLHYPLL,,,,,neo-epitope,VCRPLHYPLL,Olfactory receptor 2T3,HLA-C*07:02,MHC binding prediction,ELISPOT,1,3,0.6666666666666666,10
742519,WLIRETQPITK,,,,,neo-epitope,WLIRETQPISK,Xaa-Pro aminopeptidase 1,HLA-A*03:01,MHC binding prediction,ELISA,1,1,1.0,11
1871196,WLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1862728,WRNILLLSLH,,,,,neo-epitope,WRNILLLPLH,Caspase recruitment domain-containing protein 16,HLA-B*27:05,MHC binding prediction,ELISPOT,1,1,1.0,10
1393609,WVMPVIPAL,,,,,neo-epitope,WVMPEIPAL,,HLA-A*02:06,MHC binding prediction,ELISPOT,1,2,1.0,9
1860897,WVPVVFLTL,2.0,10.0,Prostate-specific antigen precursor,Prostate-specific antigen,,,,HLA-A*24:02,MHC binding assay,ELISA,1,2,0.5,9
1066513,YEGQVISNGF,,,,,neo-epitope,YGGQVISNGF,Adhesion G-protein coupled receptor D1,HLA-B*44:02,MHC binding prediction,ELISPOT,1,1,1.0,10
1398116,YEHEDVKEA,,,,,neo-epitope,YEDEDVKEA,Cytochrome b-c1 complex subunit 7,HLA-B*49:01,MHC binding prediction,ELISPOT,1,1,1.0,9
742520,YHSIEWAI,,,,,neo-epitope,YHPIEWAI,KIF-binding protein,HLA-B*38:01,MHC binding prediction,ELISA,1,2,1.0,8
1309319,YKLVVVGAG,4.0,12.0,GTPase NRas,GTP-binding protein GEM,,,,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0,9
1309320,YKLVVVGAV,,,,,neo-epitope,YKLVVVGAG,GTP-binding protein GEM,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0,9
754326,YLCSGSSYFV,89.0,98.0,Fragile X mental retardation 1 neighbor protein,Fragile X mental retardation 1 neighbor protein,,,,HLA-A*02:01,MHC binding prediction,ELISA,1,2,1.0,10
1335375,YLDLKGPKV,,,,,neo-epitope,DLDLKGPKV,Neuroblast differentiation-associated protein AHNAK,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5,9
1335376,YLDTDVILM,,,,,neo-epitope,YPDTDVILM,Transforming protein RhoA,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,1.0,9
534528,YLEAGPVTA,,,,,analog,YLEPGPVTA,Melanocyte protein PMEL,HLA-A*02:01,Cited reference,ELISA,1,2,1.0,9
534530,YLEPGAVTA,,,,,analog,YLEPGPVTA,Melanocyte protein PMEL,HLA-A*02:01,Cited reference,ELISA,1,2,0.5,9
534531,YLEPGPATA,,,,,analog,YLEPGPVTA,Melanocyte protein PMEL,HLA-A*02:01,Cited reference,ELISA,1,2,0.5,9
534532,YLEPGPVAA,,,,,analog,YLEPGPVTA,Melanocyte protein PMEL,HLA-A*02:01,Cited reference,ELISA,1,2,1.0,9
74638,YLEPGPVTA,280.0,288.0,Melanocyte protein Pmel 17 precursor,Melanocyte protein PMEL,,,,HLA-A*02:01,MHC binding assay,ELISA,1,6,0.8333333333333334,9
74641,YLEPGPVTV,,,,,analog,YLEPGPVTA,Melanocyte protein PMEL,HLA-A*02:01,MHC binding assay,ELISA,1,2,1.0,9
74787,YLLKPVQRI,627.0,635.0,Proto-oncogene DBL,Proto-oncogene DBL,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,1,1.0,9
1393622,YLLTDCNPA,,,,,neo-epitope,SLLTDCNPA,Ubiquitin-conjugating enzyme E2 E3,HLA-A*02:01,MHC binding prediction,ELISPOT,1,1,1.0,9
1087429,YLPGVIAAI,130.0,138.0,Metalloreductase STEAP1,Metalloreductase STEAP1,,,,HLA-A*02:01,Cited reference,ELISA,1,12,0.6666666666666666,9
1335381,YLQTDVFLV,,,,,neo-epitope,YPQTDVFLV,Cell division control protein 42 homolog (Fragment),HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5,9
74915,YLSGANLNL,605.0,613.0,Carcinoembryonic antigen-related cell adhesion molecule 5 precursor,Carcinoembryonic antigen-related cell adhesion molecule 5,,,,HLA-A*02:01,Not determined,ELISPOT,1,1,1.0,9
857812,YLSNIIPAL,,,,,neo-epitope,YLSKIIPAL,Replication factor C subunit 5,HLA-A*02:01,MHC binding prediction,ELISA,1,4,1.0,9
1310968,YLTDKDFEF,,,,,neo-epitope,YLTDEDFEF,Supervillin,HLA-A*02:01,MHC binding assay,ELISA,1,2,1.0,9
1310969,YLTDKDFEFA,,,,,neo-epitope,YLTDEDFEFA,Supervillin,HLA-A*02:01,MHC binding assay,ELISA,1,1,1.0,10
1871201,YLYDGMEHL,,,,,analog,GLYDGMEHL,Melanoma-associated antigen 10,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
509159,YLYDRLLRI,79.0,87.0,DNA replication complex GINS protein PSF1,DNA replication complex GINS protein PSF1,,,,HLA-A*02:01,MHC binding prediction,ELISA,1,4,1.0,9
857813,YLYDRLLRV,,,,,neo-epitope,YLYDRLLRI,DNA replication complex GINS protein PSF1,HLA-A*02:01,MHC binding prediction,ELISA,1,4,1.0,9
75043,YMDGTMSQV,,,,,neo-epitope,YMNGTMSQV,Tyrosinase,HLA-A*02:01,Cited reference,ELISPOT,1,1,1.0,9
1855225,YMKSLEFENK,,,,,neo-epitope,YMKSSEFENK,Serine-protein kinase ATM,HLA-A*11:01,Cited reference,ELISA,1,2,0.5,10
1855227,YMMMWDCWHA,,,,,neo-epitope,YMMMRDCWHA,Fibroblast growth factor receptor 2,HLA-A*02:01,Cited reference,ELISA,1,2,0.5,10
1855228,YMMMWDCWHAV,,,,,neo-epitope,YMMMRDCWHAV,Fibroblast growth factor receptor 2,HLA-A*02:01,Cited reference,ELISA,1,2,0.5,11
1393624,YMYLRQLFHI,,,,,neo-epitope,YMYLRQLFRI,Casein kinase I isoform alpha,HLA-A*02:01,MHC binding prediction,ELISA,1,2,1.0,10
488933,YPDTDVILM,74.0,82.0,transforming protein RhoA isoform 2 [Homo sapiens],Transforming protein RhoA,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5,9
1406323,YPPPPPALL,,,,,neo-epitope,YPPPPPALP,Neural Wiskott-Aldrich syndrome protein,HLA-B*07:02,MHC binding prediction,ELISPOT,1,1,1.0,9
1335387,YPQTDVFLV,72.0,80.0,cell division control protein 42 homolog isoform 1 precursor [Homo sapiens],Cell division control protein 42 homolog (Fragment),,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,2,0.5,9
1862763,YPVIFKSIM,,,,,neo-epitope,YPVISKSIM,T-box transcription factor TBX4,HLA-B*35:01,MHC binding prediction,ELISPOT,1,1,1.0,9
1855245,YQVSYGFRL,,,,,neo-epitope,YQGSYGFRL,Cellular tumor antigen p53,HLA-B*37:01,Cited reference,ELISA,1,2,0.5,9
607013,YQYTFPDF,,,,,neo-epitope,YQYTSPDF,Insulin-induced gene 1 protein,HLA-B*15:01,MHC binding prediction,ELISPOT,1,1,1.0,8
607014,YQYTFPDFLY,,,,,neo-epitope,YQYTSPDFLY,Insulin-induced gene 1 protein,HLA-B*15:01,MHC binding prediction,ELISPOT,1,1,1.0,10
1335393,YSARIEENI,272.0,280.0,desmoglein-3 isoform X1 [Homo sapiens],Desmoglein-3,,,,HLA-A*02:01,MHC binding assay,ELISPOT,1,4,0.5,9
607015,YSKNLNSFF,,,,,neo-epitope,YSKNLNSSF,Protein MMS22-like,HLA-B*15:01,MHC binding prediction,ELISPOT,1,1,1.0,9
75995,YTDFVGEGL,292.0,300.0,Solute carrier family 45 member 3,Solute carrier family 45 member 3,,,,HLA-C*05:01,Not determined,ELISPOT,1,2,1.0,9
859644,YVDFREYEYY,,,,,neo-epitope,YVDFREYEY,Receptor-type tyrosine-protein kinase FLT3,HLA-A*01:01,T cell assay -Mismatched MHC molecules,ELISPOT,1,4,0.75,10
1851946,YVVPGSPCL,,,,,neo-epitope,SVVPGSPCL,Tensin-1,HLA-C*03:03,MHC binding assay,ELISPOT,1,3,0.6666666666666666,9
474330,YYPPSQIAQL,,,,,neo-epitope,YYPPSQIAQL,Polyadenylate-binding protein 1,HLA-A*24:02,MHC binding prediction,ELISPOT,1,1,1.0,10
607022,YYSKNLNSF,,,,,neo-epitope,YYSKNLNSS,Protein MMS22-like,HLA-A*24:02,MHC binding prediction,ELISPOT,1,1,1.0,9
607023,YYSKNLNSFF,,,,,neo-epitope,YYSKNLNSSF,Protein MMS22-like,HLA-A*24:02,T cell assay -Biological process measured,ELISPOT,1,2,1.0,10
